etidronate has been researched along with Osteoporosis, Postmenopausal in 478 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 9.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| "The study was designed to establish the effects of HRT on osteoporosis and fractures over five years in postmenopausal women with asthma receiving regular glucocorticoids and to compare with etidronate." | 9.14 | Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. ( Campbell, IA; Douglas, JG; Francis, RM; Prescott, RJ; Reid, DM, 2009) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects." | 9.10 | Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. ( Alvarez, L; Caballería, L; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Parés, A; Peris, P; Pons, F; Roca, M; Rodés, J; Ros, I, 2003) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "The use of cyclical etidronate is not associated with an elevated risk of symptoms of peptic ulcer disease." | 7.70 | Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. ( Burger, H; Egberts, AC; Herings, RM; Leufkens, HG; Neef, C, 2000) |
| "Our clinical practice has been to offer treatment with cyclical disodium etidronate and high dose calcium supplements (1500-1600 mg/day) to all female patients with osteoporosis who are unable or unwilling to take hormone replacement therapy (HRT), and male osteoporotics." | 7.69 | Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. ( Belchetz, PE; Oldroyd, B; Orme, SM; Simpson, M; Smith, MA; Stewart, SP; Westmacott, CF, 1994) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 5.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| "The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia." | 5.14 | Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009) |
| "The study was designed to establish the effects of HRT on osteoporosis and fractures over five years in postmenopausal women with asthma receiving regular glucocorticoids and to compare with etidronate." | 5.14 | Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. ( Campbell, IA; Douglas, JG; Francis, RM; Prescott, RJ; Reid, DM, 2009) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "The purpose of this open-labeled prospective study was to compare the treatment effects of cyclical etidronate and alendronate on the lumbar bone mineral density (BMD), bone resorption, and back pain in elderly women with osteoporosis." | 5.11 | Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, or alendronate, a primary amino bisphosphonate, in healthy postmenopausal women stratified by Helicobacter pylori status." | 5.10 | 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. ( Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB, 2002) |
| "The purpose of the present study was to examine the early response of lumbar bone mineral density (BMD), bone resorption, and back pain to alendronate after treatment with cyclical etidronate in postmenopausal women with osteoporosis." | 5.10 | Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003) |
| "Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects." | 5.10 | Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. ( Alvarez, L; Caballería, L; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Parés, A; Peris, P; Pons, F; Roca, M; Rodés, J; Ros, I, 2003) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate, a primary amino bisphosphonate." | 5.09 | Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. ( Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB, 2000) |
| "To study secondary osteoporosis postmenopause in women with hemiplegia and to show the therapeutic effects of etidronate and how osteoporotic conditions relate to the activities of daily living (ADL)." | 5.09 | Prevention of secondary osteoporosis postmenopause in hemiplegia. ( Eun, SS; Hasegawa, C; Ikai, T; Kimura, C; Miyano, S; Uematsu, M, 2001) |
| "Fifty-three white women, aged 36 to 55 years, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use." | 5.08 | Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. ( Balena, R; Bremond, A; Confravreux, E; Delmas, PD; Hardouin, C; Hardy, P, 1997) |
| "The purpose of this study was to examine bone histomorphometry before and after 2 yr of a double blind trial of etidronate to determine whether etidronate was associated with the development of osteomalacia and to clarify the mechanism of action." | 5.07 | Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. ( Huffer, WE; Miller, PD; Ott, SM; Watts, NB; Woodson, GC, 1994) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| " We studied 1588 patients over the age of 50 yr who were started on cyclic etidronate (1119) or alendronate (469) in the CANDOO (Canadian Database for Osteoporosis and Osteopenia Patients) Study." | 4.82 | What predicts early fracture or bone loss on bisphosphonate therapy? ( Adachi, JD; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, R; Murray, T; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A, 2003) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Compared with use of alendronate/risedronate, use of strontium was not associated with significantly increased risk of acute coronary syndrome (rate per 1000 person-years 5." | 3.80 | Use of strontium ranelate and risk of acute coronary syndrome: cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2014) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "The findings supported the diagnosis of an acute exacerbation of a chronic risedronat-induced esophagitis caused by clindamycin." | 3.75 | [Acute exacerbation of a chronic esophagitis]. ( Göke, B; Ihrler, S; Kolligs, FT; Winkler-Budenhofer, UC, 2009) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "The use of cyclical etidronate is not associated with an elevated risk of symptoms of peptic ulcer disease." | 3.70 | Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. ( Burger, H; Egberts, AC; Herings, RM; Leufkens, HG; Neef, C, 2000) |
| "Our clinical practice has been to offer treatment with cyclical disodium etidronate and high dose calcium supplements (1500-1600 mg/day) to all female patients with osteoporosis who are unable or unwilling to take hormone replacement therapy (HRT), and male osteoporotics." | 3.69 | Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. ( Belchetz, PE; Oldroyd, B; Orme, SM; Simpson, M; Smith, MA; Stewart, SP; Westmacott, CF, 1994) |
| "The effects of vitamin D deficiency in osteopenic postmenopausal women treated with intermittent cyclical etidronate have been studied." | 3.69 | Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. ( Hackeng, WH; Koster, JC; Mulder, H, 1996) |
| "For many patients, adhering to postmenopausal osteoporosis treatment is a challenge." | 2.80 | Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. ( Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP, 2015) |
| "The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1)." | 2.80 | Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study. ( Lorenc, R; Oral, A, 2015) |
| " We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients." | 2.79 | Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. ( Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014) |
| " Overall and serious adverse events were similar between groups." | 2.79 | Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. ( Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC, 2014) |
| " Bone mineral density (BMD), bone turnover markers, new vertebral fractures, and adverse events were evaluated." | 2.78 | Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. ( Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013) |
| " Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance." | 2.78 | Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. ( Balske, A; Burgio, DE; McClung, MR; Recker, RR; Wenderoth, D, 2013) |
| " This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis." | 2.78 | A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. ( Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013) |
| "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients." | 2.77 | Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. ( Aoyagi, K; Chiba, K; Doiguchi, Y; Furuichi, I; Hashikawa, T; Motokawa, S; Norimatsu, T; Osaki, M; Shindo, H; Tatsuki, K, 2012) |
| " Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated." | 2.77 | Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. ( Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012) |
| " These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis." | 2.77 | Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Takakuwa, M, 2012) |
| "Postmenopausal osteoporosis is now a major health problem." | 2.76 | [Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis]. ( Rodríguez Rodríguez, LP, 2011) |
| "Two studies in postmenopausal women with osteoporosis provide information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i." | 2.74 | Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. ( Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009) |
| " Once-monthly dosing options might increase treatment compliance and persistence." | 2.74 | Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. ( Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009) |
| " Despite serum isoflavone profiles indicating bioavailability of the phytoestrogens, only soy isoflavones from the cotyledon and germ significantly decreased net bone resorption by 9% (P = 0." | 2.74 | Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. ( Barnes, S; Boris, ME; Jackson, GS; Martin, BR; McCabe, GP; McCabe, LD; Nolan, JR; Peacock, M; Reinwald, S; Weaver, CM, 2009) |
| " Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose." | 2.74 | Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. ( Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009) |
| "Alendronate was randomly prescribed for 41 patients and risedronate were prescribed for 43 patients." | 2.73 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008) |
| " Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6." | 2.73 | Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. ( Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D, 2007) |
| "The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture." | 2.73 | [The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007) |
| "Six postmenopausal women with diagnosed osteopenia/osteoporosis received a single oral dose of 100 nCi 41Ca for skeleton labeling." | 2.73 | Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. ( Denk, E; Fattinger, K; Häuselmann, HJ; Hillegonds, D; Hurrell, RF; Kraenzlin, M; Vogel, J; Walczyk, T, 2007) |
| " Bone mineral density, bone turnover markers, fractures, and adverse events were evaluated." | 2.73 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008) |
| " Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule." | 2.73 | Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. ( Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008) |
| "One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX)." | 2.73 | Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. ( Abe, Y; Fukao, A; Ishikawa, H, 2008) |
| "Our goal was to examine prevention of breast cancer-related bone loss in this cohort." | 2.73 | Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. ( Bhattacharya, R; Brufsky, A; Greenspan, SL; Lembersky, BC; Perera, S; Sereika, SM; Vogel, VG; Vujevich, KT, 2008) |
| "To determine the clinical recommended dosage regimen of risedronate for the treatment of involutional osteoporosis in Japanese patients, dose-response relationships for the efficacy and safety of this drug were investigated using a multi-center, randomized, double-blind, parallel group comparative design with four dose levels of risedronate (placebo, 1 mg, 2." | 2.71 | A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2003) |
| " To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials." | 2.71 | Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. ( Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB, 2003) |
| "Greater decreases in bone resorption markers were associated with greater decreases in vertebral (and nonvertebral) fractures." | 2.71 | Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. ( Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA, 2003) |
| "To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis." | 2.71 | Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003) |
| "The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis." | 2.71 | Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. ( Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004) |
| " The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium." | 2.71 | Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. ( Chen, L; Deng, X; Li, Y; Zhang, Z, 2005) |
| "Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal." | 2.71 | Monitoring of Risedronate by biochemical bone markers in clinical practice. ( Bunyaratavej, N, 2005) |
| " The time course of changes in PTH levels following cessation of dosing was unaffected by calcium supplementation." | 2.70 | Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. ( Collette, J; Eastell, R; Ethgen, D; Reginster, JY; Roumagnac, I; Russell, RG; Zegels, B, 2001) |
| "Etidronate was given cyclically (14-day courses in a dosage of 400 mg/d separated by 76-day intervals with calcium and vitamin D supplementation) and alendronate was given daily in a dosage of 10 mg/d." | 2.70 | Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. ( Béra-Louville, A; Cortet, B; Delcambre, B; Gauthier, A; Gauthier, P; Marchandise, X, 2001) |
| "Twenty-five women with postmenopausal osteoporosis (mean +/- SD: 65." | 2.69 | Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. ( Becker, P; Watts, NB, 1999) |
| "The objective of this study was to evaluate whether the pharmacological activity of cyclical etidronate therapy is sustained beyond the dosing period." | 2.69 | Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study. ( Balena, R; Blake, GM; Fogelman, I; Herd, RJ, 2000) |
| "Etidronate was well tolerated." | 2.69 | Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. ( Carbonell, J; Farrerons, J; Guañabens, N; Monegal, A; Pavesi, M; Perez-Edo, L; Renau, A; Roca, M; Torra, M, 2000) |
| "Gastric ulcers were noted in eight subjects in the aspirin group, one in the placebo group, and none in the risedronate group (P=0." | 2.69 | Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. ( Blank, MA; Krajewski, SA; Lanza, FL; Li, Z; Rack, MF, 2000) |
| "Five years of etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content, and the previously observed reduction in vertebral fracture rate in the etidronate group is maintained during at least 5 years of therapy." | 2.68 | Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. ( Genant, HK; Kollerup, G; Storm, T; Sørensen, OH; Thamsborg, G, 1996) |
| "The etidronate group was treated with etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily; this cycle was repeated every 3 months." | 2.68 | The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. ( Bakker, K; Kerkhoff, JF; Montessori, ML; Netelenbos, JC; Scheele, WH, 1997) |
| "Calcitriol has been widely used in the management of osteoporosis, but its efficiency is a matter of controversy." | 2.68 | Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. ( Bayraktar, M; Gedik, O; Gürlek, A, 1997) |
| "Etidronate was generally well tolerated and its adverse event profile was similar to that of placebo." | 2.68 | Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. ( Alexandre, C; Delmas, P; Duntze, P; Goldberg, D; Horlait, S; Khalifa, P; Kuntz, D; Pouilles, JM; Roux, C; Sebert, JL; Tremollieres, F; Treves, R, 1997) |
| "Etidronate was well tolerated with a safety profile similar to that of placebo." | 2.68 | Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) ( Balena, R; Confavreux, E; Delmas, PD; Hardouin, C; Meunier, PJ; Tupinon, I, 1997) |
| " In these studies another formulation of the drug and other dosing instructions are used." | 2.68 | A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. ( Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997) |
| "Etidronate was well tolerated during the study, with low incidences of gastrointestinal side effects and nonvertebral fractures." | 2.68 | Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. ( Chesnut, CH; Genant, HK; Harris, ST; Hoseyni, MS; Jackson, RD; Licata, AA; Miller, PD; Ross, PD; Schoenfeld, SL; Valent, DJ; Wasnich, RD; Watts, NB, 1997) |
| "We conclude that treatment of postmenopausal osteoporosis with oestrogen/progestogen for 3 years results in net spinal bone gain and a positive effect on calcium balance slightly better than that of intermittent etidronate." | 2.67 | A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. ( Charles, P; Hasling, C; Jensen, FT; Mosekilde, L, 1994) |
| " Twenty-five patients took oral disodium etidronate in a daily dosage of 200 mg in two-month courses separated by two-month intervals, with 1 g/day elemental calcium." | 2.67 | [A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis]. ( Belange, G; Chaouat, D; Chaouat, Y; Danan, S; De Vernejoul, MC; Faures Quenet, B, 1993) |
| " The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast." | 2.52 | Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. ( Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed." | 2.49 | A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. ( Yates, J, 2013) |
| "Postmenopausal osteoporosis is a chronic disease requiring treatment that balances long-term fracture efficacy against risk." | 2.48 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). ( Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R, 2012) |
| " Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important." | 2.47 | Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. ( Glendenning, P; Inderjeeth, CA; Lee, S, 2011) |
| " Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover." | 2.45 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. ( Bilezikian, JP, 2009) |
| "Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients." | 2.45 | [Etidronate for treatment of osteoporosis]. ( Asano, S; Itoh, M; Suzuki, A, 2009) |
| " The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed." | 2.45 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Rackoff, P, 2009) |
| " Current dosing schedules are often inconvenient or impractical for patients." | 2.44 | Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. ( Díaz-Curiel, M; Moro-Alvarez, MJ, 2008) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| " Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment." | 2.43 | Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. ( Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate." | 2.43 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "Osteopenia is a progressive condition that places patients at risk for increased morbidity and mortality if untreated." | 2.42 | Identifying the osteopenic patient and preventing worsening of the disease. ( Derman, R, 2003) |
| "Alendronate has demonstrated significant reductions in vertebral and nonvertebral fracture risk after 3 years." | 2.42 | An approach to postmenopausal osteoporosis treatment: a case study review. ( Kessenich, C, 2003) |
| "The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis." | 2.42 | Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. ( Emkey, R, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Etidronate disodium is an oral bisphosphonate compound known to reduce bone resorption through the inhibition of osteoclastic activity." | 2.41 | Etridronate therapy in the treatment and prevention of osteoporosis. ( Adachi, JD; Hanley, DA; Ioannidis, G, 2000) |
| "Postmenopausal osteoporosis is a widespread condition that affects the physical and emotional well-being of millions of women worldwide." | 2.41 | Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. ( Watts, NB, 2001) |
| "Key search terms were risedronate, postmenopausal osteoporosis, and fractures." | 2.41 | Risedronate for the prevention of fractures in postmenopausal osteoporosis. ( Nip, CS; Sickels, JM, 2002) |
| "New approaches to treatment of osteoporosis will emerge as our understanding of the pathogenesis increases." | 2.39 | Treatment of osteoporosis. ( Pilbeam, CC; Prestwood, KM; Raisz, LG, 1995) |
| "Osteoporosis is greatly increasing in prevalence as the population ages." | 2.39 | Office management of osteoporosis: a guide for the primary care provider. ( Daly, PA, 1995) |
| " Oestrogens are still the mainstay of drug treatment, but the risks of breast cancer versus the cardiovascular and skeletal benefits with long term use have to be assessed in the individual." | 2.39 | Current and potential future drug treatments for osteoporosis. ( Patel, S, 1996) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "Etidronate is a non-nitrogen-containing bisphosphonate." | 1.56 | History of etidronate. ( Chesnut, CH; Genant, HK; Harris, ST; Jackson, RD; Licata, AA; Miller, PD; Mysiw, WJ; Richmond, B; Valent, D; Watts, NB, 2020) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| "Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited." | 1.38 | Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. ( Anastasilakis, AD; Bratengeier, C; Papatheodorou, A; Polyzos, SA; Terpos, E; Woloszczuk, W, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| " Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0." | 1.38 | Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. ( Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH, 2012) |
| "Thirteen Japanese type 2 diabetes postmenopausal women with newly diagnosed osteoporosis (osteoporosis group) and 13 age- and weight-matched diabetic women with normal bone mineral density (control group) were enrolled in this 1-year prospective study." | 1.36 | Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. ( Hayashi, K; Kanazawa, I; Shimizu, T; Sugimoto, T; Takase, H; Yamaguchi, T, 2010) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| "The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly." | 1.35 | Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. ( Möller, G; Ringe, JD, 2009) |
| " The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated." | 1.35 | Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. ( Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| " Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence." | 1.33 | Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. ( Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005) |
| "We report the first case of pseudogout attack in the distal interphalangeal (DIP) joints during etidronate disodium therapy." | 1.33 | Pseudogout attack induced during etidronate disodium therapy. ( Anayama, S; Maekawa, S; Nakajima, I; Sato, E; Sugiyama, H; Watanabe, H; Yamada, S, 2006) |
| "Patients preferred a weekly dosing regimen with proven vertebral and non-vertebral fracture efficacy." | 1.33 | Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. ( Gold, DT; Safi, W; Trinh, H, 2006) |
| " This dosage was well tolerated with a low incidence of GI side effects." | 1.32 | Bone density changes with once weekly risedronate in postmenopausal women. ( Delaney, MF; Hurwitz, S; LeBoff, MS; Shaw, J, 2003) |
| "The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice." | 1.32 | Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003) |
| "Bisphosphonates are highly effective in postmenopausal osteoporosis." | 1.32 | Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT. ( Morishige, K; Murata, Y; Ohmichi, M; Sawada, K; Tasaka, K; Yamamoto, T, 2003) |
| "Hip fractures are the most costly and best-documented complication of osteoporosis." | 1.32 | Health-economic comparison of three recommended drugs for the treatment of osteoporosis. ( Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A, 2004) |
| "A patient suffering from symptomatic postmenopausal osteoporosis, additionally having primary hyperparathyroidism since 1995, refused a surgical resection of the adenoma of the parathyroid gland." | 1.31 | [Treatment of a solitary adenoma of the parathyroid gland with ultrasound-guided percutaneous Radio-Frequency-Tissue-Ablation (RFTA)]. ( Becker, D; Hahn, EG; Hänsler, J; Harsch, IA; Strobel, D, 2002) |
| "Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)." | 1.31 | Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. ( Iwamoto, J; Takeda, T, 2002) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| "Etidronate treatment of 5 mg/kg, 5 days/week was administered for 2 weeks and exercised on a treadmill for 30 m/min, 60 min/day, 5 days/week for 10 weeks." | 1.30 | Effects of exercise training and etidronate treatment on bone mineral density and trabecular bone in ovariectomized rats. ( Akamine, T; Goshi, N; Kurata, H; Sakou, T; Tamaki, H, 1998) |
| "This report describes the development of stress fractures during initial cycles of treatment, with recurrence of symptoms in two patients when etidronate therapy was resumed." | 1.29 | Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis. ( Collado, A; Guañabens, N; Monegal, A; Muñoz-Gómez, J; Peris, P; Pons, F, 1994) |
| "Oral etidronate has been investigated but not approved for osteoporosis therapy." | 1.29 | Postmenopausal osteoporosis: patient choices and outcomes. ( Cosman, F; Lindsay, R; Nieves, J; Walliser, J, 1995) |
| "The diagnostic criterion for postmenopausal osteoporosis was a bone mineral density (BMD) (Hologic QDR-1000) in lumbar spine and/or femoral neck more than 2 SD below the mean value corresponding to an age- and sex-matched healthy control group." | 1.29 | New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. ( de la Piedra, C; Diaz Diego, EM; Diaz Martin, MA; Disla, T; Guerrero, R; Rapado, A, 1996) |
| "Forty seven women with postmenopausal osteoporosis and at least one but no more than four vertebral compression fractures received sequential and cyclical therapy with phosphorus and etidronate (p/etid)." | 1.28 | Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. ( Anger, MS; Kowalski, L; McIntyre, DO; Miller, PD; Neal, BJ; Yanover, MJ, 1991) |
| "Etidronate can increase bone mineralization in women with osteoporosis, but will it be useful for prophylaxis? Oestrogens can prevent bone loss, but is the increased risk of breast cancer sufficient to preclude their use? Do oestrogens increase or decrease the risk of cardiovascular disease? A combination of oestrogen and progesterone may avoid the increased risk of uterine cancer but what are the effects of long term administration? Do the potential benefits of hormone therapy justify the costs and treatment of large numbers of women who without therapy would never have developed complications attributable to oestrogen lack? (Herman J: Fam Phys 1990; 18: 39-40) Given these uncertainties, is postmenopausal administration of hormones reasonable or prudent? The current literature does not provide adequate answers to these questions." | 1.28 | Selections from current literature: hormone therapy in postmenopausal women. ( Froom, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 107 (22.38) | 18.2507 |
| 2000's | 287 (60.04) | 29.6817 |
| 2010's | 78 (16.32) | 24.3611 |
| 2020's | 6 (1.26) | 2.80 |
| Authors | Studies |
|---|---|
| Thomasius, F | 2 |
| Palacios, S | 2 |
| Alam, A | 1 |
| Boolell, M | 3 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Waltman, N | 1 |
| Kupzyk, KA | 1 |
| Flores, LE | 1 |
| Mack, LR | 1 |
| Lappe, JM | 1 |
| Bilek, LD | 1 |
| Eisman, JA | 2 |
| Cortet, B | 3 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Casado, E | 1 |
| Rosas, J | 1 |
| Rubio-Terrés, C | 1 |
| Rubio-Rodríguez, D | 1 |
| Arístegui, I | 1 |
| Watts, NB | 21 |
| Chesnut, CH | 7 |
| Genant, HK | 7 |
| Harris, ST | 9 |
| Jackson, RD | 5 |
| Licata, AA | 7 |
| Miller, PD | 12 |
| Mysiw, WJ | 1 |
| Richmond, B | 1 |
| Valent, D | 2 |
| McClung, MR | 13 |
| Ebetino, FH | 2 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Ström, O | 4 |
| Liel, Y | 1 |
| Kendler, DL | 4 |
| Geusens, P | 7 |
| Zerbini, CAF | 1 |
| Minisola, S | 4 |
| Marin, F | 1 |
| Von Schacht, E | 1 |
| Dambacher, MA | 2 |
| Ringe, JD | 9 |
| Dukas, L | 1 |
| Lindsay, R | 11 |
| Lange, JL | 4 |
| Delmas, PD | 16 |
| Silverman, SL | 5 |
| Chung, HY | 3 |
| Koo, J | 1 |
| Kwon, SK | 1 |
| Kang, MI | 3 |
| Moon, SH | 2 |
| Park, JY | 1 |
| Shin, CS | 2 |
| Yoon, BK | 2 |
| Yoon, HK | 3 |
| Chang, JS | 1 |
| Chung, YS | 3 |
| Park, HM | 2 |
| Anitha, D | 1 |
| Kim, KJ | 1 |
| Lim, SK | 2 |
| Lee, T | 1 |
| Kasukawa, Y | 1 |
| Miyakoshi, N | 1 |
| Ebina, T | 1 |
| Aizawa, T | 1 |
| Hongo, M | 1 |
| Nozaka, K | 1 |
| Ishikawa, Y | 1 |
| Saito, H | 1 |
| Chida, S | 1 |
| Shimada, Y | 1 |
| Parthan, A | 1 |
| Kruse, M | 1 |
| Yurgin, N | 1 |
| Huang, J | 1 |
| Viswanathan, HN | 1 |
| Taylor, D | 1 |
| Roux, C | 14 |
| Hofbauer, LC | 1 |
| Ho, PR | 3 |
| Wark, JD | 3 |
| Zillikens, MC | 1 |
| Fahrleitner-Pammer, A | 1 |
| Hawkins, F | 1 |
| Micaelo, M | 1 |
| Papaioannou, N | 1 |
| Stone, M | 1 |
| Ferreira, I | 3 |
| Siddhanti, S | 1 |
| Wagman, RB | 2 |
| Brown, JP | 8 |
| Cairoli, E | 1 |
| Eller-Vainicher, C | 1 |
| Ulivieri, FM | 1 |
| Zhukouskaya, VV | 1 |
| Palmieri, S | 1 |
| Morelli, V | 1 |
| Beck-Peccoz, P | 1 |
| Chiodini, I | 1 |
| Gopal, GK | 1 |
| Tam, KL | 1 |
| Krishnan, SP | 1 |
| Maddern, IL | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Bolognese, MA | 3 |
| Hall, J | 1 |
| Bone, HG | 1 |
| Bonnick, S | 3 |
| van den Bergh, JP | 2 |
| Dakin, P | 1 |
| Recknor, C | 1 |
| Messori, A | 2 |
| Fadda, V | 2 |
| Maratea, D | 2 |
| Trippoli, S | 2 |
| Marinai, C | 1 |
| Recker, RR | 6 |
| Ste-Marie, LG | 5 |
| Chavassieux, P | 1 |
| Lundy, MW | 1 |
| Hagino, H | 1 |
| Yoshida, S | 1 |
| Hashimoto, J | 1 |
| Matsunaga, M | 1 |
| Tobinai, M | 1 |
| Nakamura, T | 2 |
| Agodoa, I | 1 |
| Oral, A | 1 |
| Lorenc, R | 1 |
| Adami, S | 6 |
| Giannini, S | 1 |
| Bianchi, G | 1 |
| Sinigaglia, L | 2 |
| Di Munno, O | 2 |
| Fiore, CE | 1 |
| Rossini, M | 1 |
| Kumm, J | 1 |
| Ivaska, KK | 1 |
| Rohtla, K | 1 |
| Vaananen, K | 1 |
| Tamm, A | 1 |
| Iizuka, T | 1 |
| Matsukawa, M | 1 |
| Luckey, M | 1 |
| Adachi, J | 4 |
| Saag, K | 2 |
| Greenspan, SL | 4 |
| Seeman, E | 4 |
| Boonen, S | 9 |
| Meeves, S | 1 |
| Lang, TF | 1 |
| Bilezikian, JP | 2 |
| Moro-Alvarez, MJ | 1 |
| Díaz-Curiel, M | 3 |
| Cuzick, J | 1 |
| Tosteson, AN | 1 |
| Burge, RT | 2 |
| Marshall, DA | 1 |
| Bonnick, SL | 2 |
| Beck, TJ | 1 |
| Cosman, F | 2 |
| Hochberg, MC | 3 |
| Wang, H | 1 |
| de Papp, AE | 4 |
| Iba, K | 3 |
| Takada, J | 3 |
| Hatakeyama, N | 1 |
| Ozasa, Y | 1 |
| Wada, T | 1 |
| Yamashita, T | 3 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Zikan, V | 1 |
| Stepan, JJ | 1 |
| Adachi, JD | 17 |
| Kennedy, CC | 1 |
| Papaioannou, A | 9 |
| Ioannidis, G | 5 |
| Leslie, WD | 1 |
| Walker, V | 1 |
| Campbell, IA | 1 |
| Douglas, JG | 1 |
| Francis, RM | 2 |
| Prescott, RJ | 1 |
| Reid, DM | 4 |
| Vrijens, B | 2 |
| Taylor, EB | 1 |
| Dundar, U | 1 |
| Kavuncu, V | 1 |
| Ciftci, IH | 1 |
| Evcik, D | 1 |
| Solak, O | 1 |
| Cakir, T | 1 |
| Beary, JF | 3 |
| Matzkin, E | 5 |
| Darbie, LM | 1 |
| Burgio, DE | 7 |
| Racewicz, AJ | 2 |
| Fardellone, P | 2 |
| Kruse, HP | 5 |
| Amling, M | 1 |
| van der Geest, SA | 1 |
| Möller, G | 2 |
| Binkley, N | 1 |
| Martens, MG | 1 |
| Derman, RJ | 1 |
| Greenwald, M | 1 |
| Kohles, JD | 1 |
| Bachmann, GA | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 1 |
| Wasserfallen, JB | 1 |
| Krieg, MA | 1 |
| Greiner, RA | 1 |
| Lamy, O | 1 |
| Frampton, JE | 1 |
| Rackoff, P | 1 |
| Shiraishi, A | 1 |
| Miyabe, S | 1 |
| Nakano, T | 1 |
| Umakoshi, Y | 1 |
| Ito, M | 1 |
| Mihara, M | 1 |
| Borgström, F | 4 |
| Coelho, J | 1 |
| Johansson, H | 1 |
| Oden, A | 1 |
| McCloskey, EV | 1 |
| Kanis, JA | 8 |
| Borah, B | 5 |
| Dufresne, T | 1 |
| Nurre, J | 1 |
| Phipps, R | 6 |
| Chmielewski, P | 1 |
| Wagner, L | 1 |
| Lundy, M | 1 |
| Bouxsein, M | 1 |
| Zebaze, R | 1 |
| Weaver, CM | 1 |
| Martin, BR | 1 |
| Jackson, GS | 1 |
| McCabe, GP | 1 |
| Nolan, JR | 1 |
| McCabe, LD | 1 |
| Barnes, S | 1 |
| Reinwald, S | 1 |
| Boris, ME | 1 |
| Peacock, M | 1 |
| Winkler-Budenhofer, UC | 1 |
| Ihrler, S | 1 |
| Göke, B | 1 |
| Kolligs, FT | 1 |
| Hiligsmann, M | 1 |
| Bruyère, O | 1 |
| Reginster, JY | 10 |
| Abelson, A | 2 |
| Gold, DT | 4 |
| Thomas, T | 6 |
| Waltman, NL | 1 |
| Twiss, JJ | 1 |
| Ott, CD | 1 |
| Gross, GJ | 1 |
| Lindsey, AM | 1 |
| Moore, TE | 1 |
| Berg, K | 1 |
| Kupzyk, K | 1 |
| Lee, IK | 1 |
| Park, IH | 1 |
| Kim, GS | 2 |
| Min, YK | 1 |
| Chung, DJ | 1 |
| Kim, YK | 1 |
| Choi, WH | 1 |
| Shong, MH | 1 |
| Park, JH | 1 |
| Byun, DW | 1 |
| Lee, YS | 1 |
| Kwon, NH | 1 |
| van Londen, GJ | 1 |
| Perera, S | 2 |
| Vujevich, KT | 2 |
| Sereika, SM | 3 |
| Bhattacharya, R | 2 |
| Allen, MR | 1 |
| Erickson, AM | 1 |
| Wang, X | 1 |
| Burr, DB | 1 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Masud, T | 3 |
| McClung, M | 6 |
| Ohtori, S | 3 |
| Akazawa, T | 1 |
| Murata, Y | 2 |
| Kinoshita, T | 1 |
| Yamashita, M | 1 |
| Nakagawa, K | 1 |
| Inoue, G | 3 |
| Nakamura, J | 3 |
| Orita, S | 3 |
| Ochiai, N | 3 |
| Kishida, S | 3 |
| Takaso, M | 3 |
| Eguchi, Y | 3 |
| Yamauchi, K | 3 |
| Suzuki, M | 3 |
| Aoki, Y | 3 |
| Takahashi, K | 3 |
| Yamaguchi, K | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Van Poznak, C | 1 |
| Hannon, RA | 2 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 1 |
| Barlow, D | 1 |
| Makris, A | 1 |
| Eastell, R | 10 |
| Stovall, DW | 1 |
| Beard, MK | 1 |
| Barbier, S | 1 |
| Chen, E | 3 |
| Rosenberg, E | 1 |
| Bahlous, A | 1 |
| Bouzid, K | 1 |
| Sahli, H | 1 |
| Sallami, S | 1 |
| Abdelmoula, J | 1 |
| Vestergaard, P | 3 |
| Schwartz, K | 1 |
| Pinholt, EM | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 5 |
| Klemes, AB | 1 |
| Zhou, X | 4 |
| Markopoulos, C | 2 |
| Tzoracoleftherakis, E | 2 |
| Polychronis, A | 1 |
| Venizelos, B | 2 |
| Dafni, U | 1 |
| Xepapadakis, G | 2 |
| Papadiamantis, J | 1 |
| Zobolas, V | 2 |
| Misitzis, J | 2 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 2 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 2 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Hayashi, K | 1 |
| Takase, H | 1 |
| Shimizu, T | 1 |
| Sugimoto, T | 1 |
| Yemisci, OU | 1 |
| Yalbuzdag, SA | 1 |
| Karatas, M | 1 |
| Lee, S | 1 |
| Glendenning, P | 1 |
| Inderjeeth, CA | 1 |
| Duque, G | 1 |
| Li, W | 1 |
| Adams, M | 1 |
| Xu, S | 1 |
| Misof, BM | 1 |
| Paschalis, EP | 5 |
| Blouin, S | 1 |
| Fratzl-Zelman, N | 2 |
| Klaushofer, K | 5 |
| Roschger, P | 4 |
| Qiu, S | 1 |
| Phipps, RJ | 3 |
| Palnitkar, S | 1 |
| Sudhaker Rao, D | 1 |
| Jönsson, B | 4 |
| Siris, ES | 1 |
| Tosteson, A | 1 |
| Okamoto, K | 1 |
| Inaba, M | 1 |
| Furumitsu, Y | 1 |
| Ban, A | 1 |
| Mori, N | 1 |
| Yukioka, K | 1 |
| Imanishi, Y | 1 |
| Nishizawa, Y | 2 |
| Katahira, G | 1 |
| Yoshizaki, T | 1 |
| Osugi, K | 1 |
| Miwa, S | 1 |
| Marukawa, S | 1 |
| Marukawa, K | 1 |
| Kawaguchi, Y | 1 |
| Nakato, S | 1 |
| Winzenberg, T | 1 |
| Jones, G | 1 |
| Zinnuroglu, M | 1 |
| Dincel, AS | 1 |
| Kosova, F | 1 |
| Sepici, V | 1 |
| Karatas, GK | 1 |
| Polyzos, SA | 3 |
| Anastasilakis, AD | 3 |
| Bratengeier, C | 1 |
| Woloszczuk, W | 1 |
| Papatheodorou, A | 1 |
| Terpos, E | 1 |
| Goldstein, JL | 1 |
| Klemes, A | 1 |
| Osaki, M | 1 |
| Tatsuki, K | 1 |
| Hashikawa, T | 1 |
| Norimatsu, T | 1 |
| Chiba, K | 1 |
| Motokawa, S | 1 |
| Furuichi, I | 1 |
| Doiguchi, Y | 1 |
| Aoyagi, K | 1 |
| Shindo, H | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Chin, SO | 1 |
| Koh, JM | 2 |
| Karadag-Saygi, E | 1 |
| Akyuz, G | 1 |
| Bizargity, P | 1 |
| Ay, P | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Gamsjaeger, S | 1 |
| Buchinger, B | 1 |
| Zoehrer, R | 3 |
| Lai, PS | 2 |
| Chua, SS | 2 |
| Chew, YY | 1 |
| Chan, SP | 2 |
| Zanchetta, J | 2 |
| Benhamou, CL | 5 |
| Balske, A | 3 |
| Sarley, J | 1 |
| McCullough, LK | 1 |
| Devogelaer, JP | 1 |
| Lau, CS | 1 |
| Papanastasiou, P | 1 |
| Bucci-Rechtweg, C | 1 |
| Su, G | 1 |
| Sambrook, PN | 1 |
| Frost, ML | 1 |
| Siddique, M | 1 |
| Blake, GM | 7 |
| Moore, AE | 1 |
| Marsden, PK | 1 |
| Schleyer, PJ | 1 |
| Fogelman, I | 10 |
| Hadji, P | 1 |
| Zanchetta, JR | 4 |
| Russo, L | 1 |
| Recknor, CP | 1 |
| Saag, KG | 2 |
| McKiernan, FE | 1 |
| Alam, J | 1 |
| Krege, JH | 1 |
| Lakshmanan, MC | 1 |
| Masica, DN | 1 |
| Mitlak, BH | 1 |
| Stock, JL | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Cooper, C | 3 |
| Lorenc, RS | 1 |
| Rizzoli, R | 5 |
| Bae, SJ | 1 |
| Kim, BJ | 1 |
| Lim, KH | 1 |
| Lee, SH | 1 |
| Kim, HK | 1 |
| Horlait, S | 3 |
| Atlan, P | 1 |
| Racewicz, A | 2 |
| Man, Z | 4 |
| Eusebio, RA | 2 |
| Delmas, P | 3 |
| Takakuwa, M | 1 |
| Iwamoto, J | 9 |
| Kuniyoshi, K | 2 |
| Ishikawa, T | 2 |
| Miyagi, M | 2 |
| Kamoda, H | 2 |
| Kubota, G | 2 |
| Sakuma, Y | 2 |
| Oikawa, Y | 2 |
| Inage, K | 2 |
| Sainoh, T | 2 |
| Ozawa, T | 1 |
| Toyone, T | 2 |
| Chau, D | 1 |
| Becker, DL | 1 |
| Coombes, ME | 1 |
| Goeree, R | 2 |
| Wenderoth, D | 3 |
| Yates, J | 1 |
| Tlustochowicz, W | 2 |
| Eusebio, R | 2 |
| Balske, AM | 1 |
| Olszynski, WP | 7 |
| Recker, R | 2 |
| Wang, G | 1 |
| Zhu, Z | 1 |
| Lei, C | 1 |
| Li, M | 2 |
| Liu, F | 1 |
| Mao, Y | 1 |
| Yu, Z | 1 |
| Liu, M | 1 |
| Zhao, X | 1 |
| Tang, T | 1 |
| Peris, P | 3 |
| Atkinson, EJ | 1 |
| Gössl, M | 1 |
| Kane, TL | 1 |
| McCready, LK | 1 |
| Lerman, A | 1 |
| Khosla, S | 2 |
| McGregor, UI | 1 |
| Rodríguez Rodríguez, LP | 1 |
| Matsubara, M | 1 |
| Nakamura, K | 1 |
| Morita, S | 1 |
| Kashima, I | 1 |
| Nuzzo, S | 1 |
| Lafage-Proust, MH | 1 |
| Martin-Badosa, E | 1 |
| Boivin, G | 1 |
| Alexandre, C | 3 |
| Peyrin, F | 1 |
| Hänsler, J | 1 |
| Harsch, IA | 1 |
| Strobel, D | 1 |
| Hahn, EG | 1 |
| Becker, D | 1 |
| Steinbuch, M | 1 |
| D'Agostino, RB | 1 |
| Mandel, JS | 1 |
| Gabrielson, E | 1 |
| Stemhagen, A | 1 |
| Hofman, A | 1 |
| Cranney, A | 8 |
| Tugwell, P | 7 |
| Weaver, B | 3 |
| Zytaruk, N | 3 |
| Robinson, V | 4 |
| Shea, B | 6 |
| Wells, G | 7 |
| Guyatt, G | 6 |
| Kherani, RB | 1 |
| Thomson, AB | 2 |
| Marshall, JK | 1 |
| Hunt, RH | 2 |
| Provenza, JM | 2 |
| Lanza, FL | 3 |
| Royer, MG | 1 |
| Li, Z | 8 |
| Blank, MA | 3 |
| Diez-Perez, A | 1 |
| Tremaine, WJ | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Baranauskaite, A | 1 |
| Savickiene, A | 1 |
| Eriksen, EF | 6 |
| Melsen, F | 3 |
| Sod, E | 3 |
| Barton, I | 4 |
| Chines, A | 5 |
| Takeda, T | 8 |
| Minne, HW | 2 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Deal, CL | 1 |
| Zethraeus, N | 1 |
| Josse, RG | 1 |
| Hamdy, RC | 3 |
| Hughes, RA | 1 |
| Manhart, MD | 4 |
| Calligeros, D | 1 |
| Felsenberg, D | 5 |
| Bartl, R | 1 |
| Sorensen, OH | 3 |
| Crawford, GM | 1 |
| Mulder, H | 5 |
| Hosking, DJ | 4 |
| Gennari, C | 2 |
| Mellstrom, D | 1 |
| Pack, S | 2 |
| Delaney, MF | 2 |
| Hurwitz, S | 1 |
| Shaw, J | 1 |
| LeBoff, MS | 1 |
| Hamilton, B | 1 |
| McCoy, K | 1 |
| Taggart, H | 1 |
| Shiraki, M | 2 |
| Fukunaga, M | 2 |
| Kushida, K | 2 |
| Kishimoto, H | 2 |
| Taketani, Y | 1 |
| Minaguchi, H | 1 |
| Inoue, T | 2 |
| Morita, R | 1 |
| Morii, H | 3 |
| Yamamoto, K | 2 |
| Ohashi, Y | 2 |
| Orimo, H | 2 |
| Kasibhatla, C | 2 |
| Brown, J | 3 |
| Derman, R | 1 |
| Morishige, K | 1 |
| Yamamoto, T | 1 |
| Sawada, K | 1 |
| Ohmichi, M | 1 |
| Tasaka, K | 1 |
| Kitatani, K | 1 |
| Nakatsuka, K | 1 |
| Naka, H | 1 |
| Miki, T | 1 |
| Garnero, P | 1 |
| Ichimura, S | 4 |
| Uzawa, M | 3 |
| Matsu, K | 1 |
| Dufresne, TE | 4 |
| Chmielewski, PA | 3 |
| Johnson, TD | 3 |
| Hosking, D | 3 |
| Andia, JC | 1 |
| Välimäki, M | 1 |
| Benhamou, L | 1 |
| Yacik, C | 1 |
| Rybak-Feglin, A | 1 |
| Petruschke, RA | 2 |
| Zaru, L | 1 |
| Santora, AC | 1 |
| Yood, RA | 1 |
| Emani, S | 1 |
| Reed, JI | 1 |
| Lewis, BE | 1 |
| Charpentier, M | 1 |
| Lydick, E | 1 |
| Sebaldt, RJ | 3 |
| Ferko, N | 1 |
| Puglia, M | 1 |
| Tenenhouse, A | 2 |
| Boulos, P | 1 |
| Hanley, DA | 5 |
| Josse, R | 3 |
| Murray, TM | 1 |
| Petrie, A | 2 |
| Goldsmith, CH | 2 |
| Ettinger, MP | 2 |
| Guañabens, N | 3 |
| Parés, A | 1 |
| Ros, I | 1 |
| Alvarez, L | 1 |
| Pons, F | 2 |
| Caballería, L | 1 |
| Monegal, A | 3 |
| Martínez de Osaba, MJ | 1 |
| Roca, M | 2 |
| Rodés, J | 1 |
| Waldegger, L | 1 |
| Harrington, JT | 1 |
| Brandi, ML | 4 |
| Civitelli, R | 2 |
| Grauer, A | 3 |
| Sawka, AM | 1 |
| Murray, T | 1 |
| Kessenich, C | 1 |
| Wei, GS | 1 |
| Jackson, JL | 1 |
| Hatzigeorgiou, C | 1 |
| Tofferi, JK | 1 |
| Curković, B | 1 |
| Songcharoen, S | 1 |
| Chines, AA | 3 |
| Johnell, O | 4 |
| Brecht, JG | 2 |
| Möhrke, W | 2 |
| Oestreich, A | 2 |
| Huppertz, E | 2 |
| Itabashi, A | 2 |
| Kaneda, K | 1 |
| Nawata, H | 1 |
| Barton, IP | 6 |
| van Staa, TP | 1 |
| Marx, J | 1 |
| Mellström, DD | 1 |
| Goemaere, S | 1 |
| Ishida, Y | 1 |
| Kawai, S | 1 |
| Johnson, T | 1 |
| El-Hajj Fuleihan, G | 1 |
| Zizic, TM | 2 |
| Emkey, R | 3 |
| Keller, MI | 1 |
| Sarioglu, M | 1 |
| Tuzun, C | 1 |
| Unlu, Z | 1 |
| Tikiz, C | 1 |
| Taneli, F | 1 |
| Uyanik, BS | 1 |
| Rosen, CJ | 2 |
| Miller, P | 1 |
| Broy, S | 1 |
| Kagan, R | 2 |
| Thompson, DE | 2 |
| Dorst, A | 1 |
| Faber, H | 1 |
| Kipshoven, C | 1 |
| Rovati, LC | 1 |
| Setnikar, I | 1 |
| Leung, JY | 1 |
| Ho, AY | 1 |
| Ip, TP | 1 |
| Lee, G | 1 |
| Kung, AW | 2 |
| Chapurlat, RD | 3 |
| Barger-Lux, J | 1 |
| Christensen, PM | 1 |
| Sørensen, HA | 1 |
| Tanriverdi, HA | 1 |
| Barut, A | 1 |
| Sarikaya, S | 1 |
| Melton, LJ | 1 |
| Ritman, EL | 2 |
| Jorgensen, SM | 2 |
| Liu, S | 2 |
| Sacha, J | 1 |
| Turner, RT | 2 |
| Høiseth, A | 1 |
| Palomba, S | 1 |
| Orio, F | 1 |
| Manguso, F | 1 |
| Falbo, A | 1 |
| Russo, T | 1 |
| Tolino, A | 1 |
| Tauchmanovà, L | 1 |
| Colao, A | 1 |
| Doldo, P | 1 |
| Mastrantonio, P | 1 |
| Zullo, F | 1 |
| Stevenson, M | 1 |
| Jones, ML | 1 |
| De Nigris, E | 1 |
| Brewer, N | 1 |
| Davis, S | 1 |
| Oakley, J | 1 |
| Meredith, MP | 2 |
| White, NJ | 1 |
| Perry, CM | 1 |
| Pande, I | 1 |
| Rackoff, PJ | 1 |
| Sebba, A | 2 |
| Köşüş, A | 1 |
| Capar, M | 1 |
| Köşüş, N | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Heaney, RP | 3 |
| Valent, DJ | 2 |
| Cramer, JA | 1 |
| Amonkar, MM | 1 |
| Hebborn, A | 1 |
| Altman, R | 1 |
| Poole, KE | 1 |
| Warburton, EA | 1 |
| Reeve, J | 1 |
| Dunlap, LE | 1 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| Maricic, M | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Sato, Y | 3 |
| Hooper, MJ | 1 |
| Ebeling, PR | 1 |
| Roberts, AP | 1 |
| Graham, JJ | 1 |
| Nicholson, GC | 1 |
| D'Emden, M | 1 |
| Ernst, TF | 1 |
| Li, Y | 1 |
| Zhang, Z | 1 |
| Deng, X | 1 |
| Chen, L | 1 |
| Reach, G | 1 |
| Lespessailles, E | 1 |
| Epstein, S | 1 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Lee, E | 1 |
| Wutoh, AK | 1 |
| Xue, Z | 1 |
| Hillman, JJ | 1 |
| Zuckerman, IH | 1 |
| Gass, M | 1 |
| Dawson-Hughes, B | 1 |
| Carlsson, A | 1 |
| Sintonen, H | 1 |
| Haentjens, P | 1 |
| Burge, R | 1 |
| Sibonga, JD | 1 |
| Watanabe, H | 1 |
| Yamada, S | 1 |
| Anayama, S | 1 |
| Sato, E | 1 |
| Maekawa, S | 1 |
| Sugiyama, H | 1 |
| Nakajima, I | 1 |
| Kiel, DP | 1 |
| Hochberg, M | 1 |
| Burnett, SM | 1 |
| Penning-van Beest, FJ | 2 |
| Goettsch, WG | 1 |
| Erkens, JA | 2 |
| Herings, RM | 3 |
| Ilter, E | 1 |
| Karalok, H | 1 |
| Tufekci, EC | 1 |
| Batur, O | 1 |
| Hofstaetter, JG | 1 |
| Durchschlag, E | 2 |
| Fratzl, P | 3 |
| Blackhouse, G | 1 |
| Langdahl, B | 1 |
| Orcel, P | 1 |
| Bhattacharya, RK | 1 |
| Brufsky, A | 2 |
| Vogel, VG | 2 |
| Bornstein, MM | 1 |
| Oberli, K | 1 |
| Stauffer, E | 1 |
| Buser, D | 1 |
| Kendler, D | 3 |
| Weryha, G | 2 |
| Marques-Neto, JF | 2 |
| Gaines, KA | 1 |
| Verbruggen, N | 2 |
| Melton, ME | 2 |
| Briot, K | 1 |
| Trémollières, F | 3 |
| Ozgocmen, S | 1 |
| Kaya, H | 1 |
| Fadillioglu, E | 1 |
| Yilmaz, Z | 1 |
| Pols, HA | 1 |
| Cahall, D | 1 |
| Keen, R | 1 |
| Jodar, E | 1 |
| Iolascon, G | 1 |
| Varbanov, A | 1 |
| Mann, B | 1 |
| Safi, W | 1 |
| Trinh, H | 1 |
| Lambrinoudaki, I | 1 |
| Christodoulakos, G | 1 |
| Botsis, D | 1 |
| Pasion, EG | 1 |
| Sivananthan, SK | 1 |
| Chen, SH | 1 |
| Chen, YJ | 1 |
| Mirasol, R | 1 |
| Tay, BK | 1 |
| Shah, GA | 1 |
| Khan, MA | 1 |
| Tam, F | 1 |
| Hall, BJ | 1 |
| Thiebaud, D | 1 |
| Imoto, K | 1 |
| Phillips, MB | 1 |
| Brookhart, MA | 2 |
| Avorn, J | 1 |
| Katz, JN | 2 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Altintaş, F | 1 |
| Ozkut, AT | 1 |
| Beyzadeoğlu, T | 1 |
| Eren, A | 1 |
| Güven, M | 1 |
| Yanik, B | 1 |
| Bavbek, N | 1 |
| Yanik, T | 1 |
| Inegöl, I | 1 |
| Kanbay, M | 1 |
| Turgut, FH | 1 |
| Uz, E | 1 |
| Akçay, A | 1 |
| Bunyaratavej, N | 1 |
| Denk, E | 1 |
| Hillegonds, D | 1 |
| Hurrell, RF | 1 |
| Vogel, J | 1 |
| Fattinger, K | 1 |
| Häuselmann, HJ | 1 |
| Kraenzlin, M | 1 |
| Walczyk, T | 1 |
| Giljević, Z | 1 |
| Vlak, T | 1 |
| Moro Alvarez, MJ | 1 |
| Griffith, L | 3 |
| Krolicki, N | 3 |
| Robinson, VA | 2 |
| Shea, BJ | 2 |
| Waldegger, LM | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| Strampel, W | 1 |
| Mamdani, M | 1 |
| Kopp, A | 1 |
| Hawker, G | 1 |
| McKeever, CD | 2 |
| D'Amelio, P | 1 |
| Grimaldi, A | 1 |
| Di Bella, S | 1 |
| Tamone, C | 1 |
| Brianza, SZ | 1 |
| Ravazzoli, MG | 1 |
| Bernabei, P | 1 |
| Cristofaro, MA | 1 |
| Pescarmona, GP | 1 |
| Isaia, G | 3 |
| Schofield, PJ | 1 |
| Cahall, DL | 1 |
| Cline, GA | 1 |
| Grima, DT | 2 |
| Thompson, MF | 1 |
| Pasquale, MK | 1 |
| Välimäki, MJ | 1 |
| Farrerons-Minguella, J | 1 |
| Halse, J | 1 |
| Kröger, H | 1 |
| Maroni, M | 1 |
| Muñoz-Torres, M | 1 |
| Sääf, M | 1 |
| Snorre Øfjord, E | 1 |
| Cesareo, R | 1 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Tanaka, I | 1 |
| Oshima, H | 1 |
| Abe, Y | 1 |
| Ishikawa, H | 1 |
| Fukao, A | 1 |
| Wells, GA | 1 |
| Peterson, J | 2 |
| Boucher, M | 2 |
| Coyle, D | 2 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Goulis, DG | 2 |
| Gerou, S | 2 |
| Koukoulis, G | 1 |
| Kita, M | 2 |
| Avramidis, A | 2 |
| Luisetto, G | 1 |
| Silvestri, S | 1 |
| Agnusdei, D | 1 |
| Gentilella, R | 1 |
| Nuti, R | 1 |
| Hustad, CM | 1 |
| Mahlis, EM | 1 |
| Anić, B | 1 |
| Olson, M | 1 |
| Dane, C | 1 |
| Dane, B | 1 |
| Cetin, A | 1 |
| Erginbas, M | 1 |
| Koukoulis, GN | 1 |
| Efstathiadou, Z | 1 |
| Lembersky, BC | 1 |
| Ioachimescu, A | 1 |
| Licata, A | 1 |
| Gärtner, R | 1 |
| Cadarette, SM | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Solomon, DH | 2 |
| Arase, Y | 1 |
| Suzuki, F | 1 |
| Suzuki, Y | 1 |
| Akuta, N | 1 |
| Kobayashi, M | 1 |
| Kawamura, Y | 1 |
| Yatsuji, H | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Katsumata, T | 1 |
| Ohnishi, H | 1 |
| Sakurama, T | 1 |
| Jee, WS | 2 |
| Lin, BY | 1 |
| Ma, YF | 1 |
| Ke, HZ | 2 |
| Prestwood, KM | 1 |
| Pilbeam, CC | 1 |
| Raisz, LG | 1 |
| Sternberg, JL | 1 |
| Steiniche, T | 4 |
| Søgaard, CH | 1 |
| Thomsen, JS | 1 |
| Wronski, TJ | 3 |
| Loeliger, EA | 2 |
| Diamond, T | 2 |
| McGuigan, L | 1 |
| Barbagallo, S | 1 |
| Bryant, C | 1 |
| Boyce, RW | 3 |
| Paddock, CL | 2 |
| Gleason, JR | 1 |
| Sletsema, WK | 1 |
| Ebert, DC | 1 |
| Stevens, ML | 1 |
| Youngs, TA | 1 |
| Gundersen, HJ | 1 |
| Baumann, BD | 1 |
| Kotowicz, M | 1 |
| Collado, A | 1 |
| Muñoz-Gómez, J | 1 |
| Orme, SM | 1 |
| Simpson, M | 1 |
| Stewart, SP | 1 |
| Oldroyd, B | 1 |
| Westmacott, CF | 1 |
| Smith, MA | 1 |
| Belchetz, PE | 1 |
| Carrière, EG | 1 |
| Koopmans, PP | 1 |
| van Bronswijk, H | 1 |
| Lekkerkerker, JF | 1 |
| Hasling, C | 2 |
| Charles, P | 3 |
| Jensen, FT | 1 |
| Singer, F | 1 |
| Hughes, JR | 1 |
| Pembroke, AC | 1 |
| Lacy, ME | 1 |
| Bevan, JA | 1 |
| Geddes, AD | 1 |
| Struys, A | 1 |
| Ott, SM | 1 |
| Woodson, GC | 2 |
| Huffer, WE | 1 |
| Chaouat, D | 1 |
| Belange, G | 1 |
| Danan, S | 1 |
| De Vernejoul, MC | 1 |
| Faures Quenet, B | 1 |
| Chaouat, Y | 1 |
| Heyneman, CA | 1 |
| Wasnich, RD | 3 |
| Ross, P | 2 |
| Eisinger, J | 1 |
| Clairet, D | 1 |
| Storm, T | 3 |
| Thamsborg, G | 3 |
| Evans, RA | 1 |
| Somers, NM | 1 |
| Dunstan, CR | 1 |
| Royle, H | 1 |
| Kos, S | 1 |
| Allen, SH | 1 |
| Nieves, J | 1 |
| Walliser, J | 1 |
| Daly, PA | 1 |
| Ma, Y | 1 |
| Chen, Y | 1 |
| Gasser, J | 1 |
| Li, XJ | 1 |
| Kimmel, DB | 1 |
| Lafage, MH | 1 |
| Anderson, FH | 1 |
| Torgerson, DJ | 2 |
| Forbes, RB | 1 |
| Grant, DJ | 1 |
| MacWalter, RS | 1 |
| Kollerup, G | 1 |
| Sørensen, OH | 2 |
| Guerrero, R | 1 |
| Diaz Martin, MA | 1 |
| Diaz Diego, EM | 1 |
| Disla, T | 1 |
| Rapado, A | 1 |
| de la Piedra, C | 1 |
| Koster, JC | 1 |
| Hackeng, WH | 2 |
| Patel, S | 1 |
| Balena, R | 5 |
| Confravreux, E | 1 |
| Hardouin, C | 2 |
| Hardy, P | 1 |
| Bremond, A | 1 |
| Montessori, ML | 1 |
| Scheele, WH | 1 |
| Netelenbos, JC | 2 |
| Kerkhoff, JF | 1 |
| Bakker, K | 1 |
| Herd, RJ | 6 |
| Tobias, JH | 1 |
| Dalzell, N | 1 |
| Pazianas, M | 1 |
| Chambers, TJ | 1 |
| Gürlek, A | 1 |
| Bayraktar, M | 1 |
| Gedik, O | 1 |
| Cardona, JM | 1 |
| Pastor, E | 1 |
| Pouilles, JM | 1 |
| Sebert, JL | 1 |
| Goldberg, D | 1 |
| Treves, R | 1 |
| Khalifa, P | 1 |
| Duntze, P | 1 |
| Kuntz, D | 1 |
| Heikkinen, JE | 1 |
| Selander, KS | 1 |
| Laitinen, K | 1 |
| Arnala, I | 1 |
| Väänänen, HK | 1 |
| Lyritis, GP | 1 |
| Tsakalakos, N | 1 |
| Paspati, I | 1 |
| Skarantavos, G | 1 |
| Galanos, A | 1 |
| Androulakis, C | 1 |
| Axelrod, DW | 2 |
| Meunier, PJ | 2 |
| Confavreux, E | 1 |
| Tupinon, I | 1 |
| Patel, R | 4 |
| Clemmesen, B | 1 |
| Ravn, P | 1 |
| Zegels, B | 2 |
| Taquet, AN | 1 |
| Christiansen, C | 1 |
| Ross, PD | 1 |
| Hoseyni, MS | 3 |
| Schoenfeld, SL | 1 |
| Mortensen, L | 1 |
| Bekker, PJ | 1 |
| Digennaro, J | 1 |
| Johnston, CC | 1 |
| Wimalawansa, SJ | 1 |
| Golden, BD | 1 |
| Neff, M | 1 |
| Kissling, R | 1 |
| Qin, L | 1 |
| Lopes, P | 1 |
| Tamaki, H | 1 |
| Akamine, T | 1 |
| Goshi, N | 1 |
| Kurata, H | 1 |
| Sakou, T | 1 |
| Mulcahy, B | 1 |
| Thompson, AV | 1 |
| Donnelly, S | 1 |
| Keen, RW | 1 |
| Doyle, DV | 1 |
| Spector, TD | 1 |
| Yaşil, S | 1 |
| Cömlekçi, A | 1 |
| Güneri, A | 1 |
| Bolanca, S | 1 |
| Korsić, M | 1 |
| Dekanić, D | 1 |
| Cvijetić, S | 1 |
| Khan, AA | 1 |
| Becker, P | 1 |
| Rosner, AJ | 1 |
| Torrance, GW | 1 |
| Bradley, C | 1 |
| Willison, DJ | 1 |
| Preston, NG | 1 |
| Beauchesne, MF | 1 |
| Miller, PF | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Hu, B | 1 |
| Mo, LE | 1 |
| Ullom-Minnich, P | 1 |
| Terranova, R | 1 |
| Luca, S | 1 |
| Hangartner, T | 1 |
| Keller, M | 1 |
| Reginster, J | 1 |
| Hooper, M | 1 |
| Lund, B | 1 |
| Ethgen, D | 3 |
| Roumagnac, I | 2 |
| Marc, J | 1 |
| Prezelj, J | 1 |
| Komel, R | 1 |
| Kocijancic, A | 1 |
| Heath, DA | 1 |
| Bullivant, BG | 1 |
| Boiven, C | 1 |
| Kessenich, CR | 1 |
| Ribot, C | 1 |
| Smith, R | 2 |
| Struijs, A | 1 |
| Smals, A | 1 |
| de Witte, SA | 1 |
| Farrerons, J | 1 |
| Perez-Edo, L | 1 |
| Renau, A | 1 |
| Carbonell, J | 1 |
| Torra, M | 1 |
| Pavesi, M | 1 |
| Preston, N | 1 |
| Bruni, V | 1 |
| Bianchini, D | 1 |
| Becorpi, A | 1 |
| Lombardi, P | 1 |
| Campagnoli, C | 1 |
| Ferrari, A | 1 |
| Marchesoni, T | 1 |
| Paran, D | 1 |
| Elkayam, O | 1 |
| Yaron, M | 1 |
| Caspi, D | 1 |
| Burger, H | 1 |
| Egberts, AC | 1 |
| Neef, C | 1 |
| Leufkens, HG | 1 |
| Leder, BZ | 1 |
| Kronenberg, HM | 1 |
| Kuntz, KM | 1 |
| Lems, WF | 1 |
| Dijkmans, BA | 1 |
| Fairney, A | 1 |
| Kyd, P | 1 |
| Thomas, E | 1 |
| Wilson, J | 1 |
| Chapurlat, R | 1 |
| Papapoulos, SE | 2 |
| Compston, JE | 1 |
| Rack, MF | 1 |
| Krajewski, SA | 1 |
| Russell, RG | 1 |
| Collette, J | 1 |
| Zippel, H | 1 |
| Bensen, WG | 1 |
| Crandall, C | 1 |
| Sahota, O | 1 |
| Fowler, I | 1 |
| Blackwell, PJ | 1 |
| Lawson, N | 1 |
| Cawte, SA | 1 |
| San, P | 1 |
| Ikai, T | 1 |
| Uematsu, M | 1 |
| Eun, SS | 1 |
| Kimura, C | 1 |
| Hasegawa, C | 1 |
| Miyano, S | 1 |
| Irani, M | 1 |
| Welch, V | 2 |
| Davidson, M | 1 |
| Moffett, AH | 1 |
| Baylink, DJ | 1 |
| Crusan, CE | 1 |
| Hyldstrup, L | 1 |
| Jørgensen, JT | 1 |
| Sørensen, TK | 1 |
| Baeksgaard, L | 1 |
| Dunn, CJ | 1 |
| Goa, KL | 1 |
| McCormack, J | 1 |
| Shiota, E | 1 |
| Tsuchiya, K | 1 |
| Yamaoka, K | 1 |
| Kawano, O | 1 |
| Umland, EM | 1 |
| Boyce, EG | 1 |
| Béra-Louville, A | 1 |
| Gauthier, P | 1 |
| Gauthier, A | 1 |
| Marchandise, X | 1 |
| Delcambre, B | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Gomez-Panzani, E | 1 |
| Bannwarth, B | 1 |
| Sickels, JM | 1 |
| Nip, CS | 1 |
| Iglesias, CP | 1 |
| Bearne, A | 1 |
| Bose, U | 1 |
| Hodsman, AB | 1 |
| Emkey, RD | 1 |
| Alsayed, N | 1 |
| Davie, MW | 1 |
| Sambrook, P | 1 |
| Silberstein, EB | 1 |
| Schnur, W | 1 |
| Pertuiset, E | 1 |
| Neal, BJ | 1 |
| McIntyre, DO | 1 |
| Yanover, MJ | 2 |
| Anger, MS | 1 |
| Kowalski, L | 1 |
| Walsh, BW | 1 |
| Schiff, I | 1 |
| Attie, MF | 1 |
| Lockefeer, JH | 1 |
| Ziegler, R | 1 |
| Forys, VA | 1 |
| Papapoulos, S | 1 |
| Gallacher, SJ | 1 |
| Boyle, IT | 1 |
| Capell, HA | 1 |
| Stone, MD | 1 |
| Froom, J | 1 |
| Riggs, BL | 1 |
| Bockman, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy[NCT00919711] | Phase 3 | 870 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide[NCT00130403] | Phase 4 | 290 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| HRT and/or Etidronate in the Prevention and Treatment of Osteoporosis and Fractures in Post-Menopausal Patients With Asthma Receiving Long-Term Oral and/or Inhaled Glucocorticoids:a Randomised Factorial Trial[NCT00376662] | Phase 4 | 750 participants | Interventional | 1992-08-31 | Completed | ||
| The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology[NCT02367846] | Phase 4 | 6 participants (Actual) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover[NCT02630797] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-01-12 | Active, not recruiting | ||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial[NCT01572545] | 91 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.[NCT00541658] | Phase 3 | 923 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)[NCT00089791] | Phase 3 | 7,808 participants (Actual) | Interventional | 2004-08-01 | Completed | ||
| The Pharmacokinetics and Pharmacodynamics Study of Intravenous Zoledronic Acid in Chinese Subjects With Low Bone Mass or Osteoporosis: a Randomized Placebo-controlled Trail[NCT04719650] | Phase 4 | 64 participants (Anticipated) | Interventional | 2021-10-31 | Not yet recruiting | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.[NCT01854086] | 150 participants (Anticipated) | Observational [Patient Registry] | 2013-09-30 | Not yet recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double[NCT00092040] | Phase 3 | 936 participants (Actual) | Interventional | 2003-03-18 | Completed | ||
| A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.[NCT00268632] | Phase 3 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans[NCT02565602] | 10 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health[NCT01053481] | Early Phase 1 | 25 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)[NCT00353080] | Phase 3 | 171 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study[NCT02808988] | Phase 4 | 47 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis[NCT00853723] | Phase 2 | 105 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)[NCT00118508] | 87 participants (Actual) | Interventional | 2003-05-31 | Completed | |||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.0 |
| Denosumab 60 mg Q6M | 1.4 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 1.1 |
| Denosumab 60 mg Q6M | 3.4 |
Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1 (NCT00919711)
Timeframe: Baseline to month 1
| Intervention | Percent Change From Baseline (Median) |
|---|---|
| Risedronate 150 mg QM | -17.0 |
| Denosumab 60 mg Q6M | -77.7 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.5 |
| Denosumab 60 mg Q6M | 2.0 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 5 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 6 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 5 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 4 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 2 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 3 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 2 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 3 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 239 |
| 35 mg After Breakfast | 231 |
| 35 mg Before Breakfast | 233 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 269 |
| 35 mg After Breakfast | 263 |
| 35 mg Before Breakfast | 267 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 255 |
| 35 mg After Breakfast | 255 |
| 35 mg Before Breakfast | 254 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 268 |
| 35 mg After Breakfast | 259 |
| 35 mg Before Breakfast | 268 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.900 |
| 35 mg After Breakfast | 2.148 |
| 35 mg Before Breakfast | 2.164 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.431 |
| 35 mg After Breakfast | 1.986 |
| 35 mg Before Breakfast | 2.047 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.530 |
| 35 mg After Breakfast | 2.108 |
| 35 mg Before Breakfast | 2.328 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.120 |
| 35 mg After Breakfast | 1.385 |
| 35 mg Before Breakfast | 1.246 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.180 |
| 35 mg After Breakfast | 1.507 |
| 35 mg Before Breakfast | 1.717 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.155 |
| 35 mg After Breakfast | 1.482 |
| 35 mg Before Breakfast | 1.717 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.772 |
| 35 mg After Breakfast | 3.691 |
| 35 mg Before Breakfast | 3.828 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.056 |
| 35 mg After Breakfast | 4.152 |
| 35 mg Before Breakfast | 4.246 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.186 |
| 35 mg After Breakfast | 2.732 |
| 35 mg Before Breakfast | 2.764 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.297 |
| 35 mg After Breakfast | 2.854 |
| 35 mg Before Breakfast | 2.819 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -32.572 |
| 35 mg After Breakfast | -34.769 |
| 35 mg Before Breakfast | -34.824 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -33.394 |
| 35 mg After Breakfast | -36.143 |
| 35 mg Before Breakfast | -36.810 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -23.386 |
| 35 mg After Breakfast | -25.141 |
| 35 mg Before Breakfast | -25.191 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.273 |
| 35 mg After Breakfast | -33.680 |
| 35 mg Before Breakfast | -32.582 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.367 |
| 35 mg After Breakfast | -32.802 |
| 35 mg Before Breakfast | -32.829 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.895 |
| 35 mg After Breakfast | -33.450 |
| 35 mg Before Breakfast | -33.507 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -41.451 |
| 35 mg After Breakfast | -49.253 |
| 35 mg Before Breakfast | -48.752 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.155 |
| 35 mg After Breakfast | -51.985 |
| 35 mg Before Breakfast | -52.538 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.172 |
| 35 mg After Breakfast | -48.724 |
| 35 mg Before Breakfast | -47.703 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.410 |
| 35 mg After Breakfast | -49.185 |
| 35 mg Before Breakfast | -50.048 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.613 |
| 35 mg After Breakfast | 1.748 |
| 35 mg Before Breakfast | 1.685 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.809 |
| 35 mg After Breakfast | 2.130 |
| 35 mg Before Breakfast | 2.099 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 4.147 |
| 35 mg After Breakfast | 5.205 |
| 35 mg Before Breakfast | 5.068 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 4.352 |
| 35 mg After Breakfast | 5.506 |
| 35 mg Before Breakfast | 5.396 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg IRBB | 3.069 |
| 35 mg DRFB + DRBB | 3.334 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.685 |
| 35 mg After Breakfast | 2.816 |
| 35 mg Before Breakfast | 2.529 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.035 |
| 35 mg After Breakfast | 3.293 |
| 35 mg Before Breakfast | 3.357 |
(NCT00541658)
Timeframe: 52 weeks / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.069 |
| 35 mg After Breakfast | 3.302 |
| 35 mg Before Breakfast | 3.365 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.331 |
| 35 mg After Breakfast | -46.781 |
| 35 mg Before Breakfast | -46.054 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.386 |
| 35 mg After Breakfast | -49.183 |
| 35 mg Before Breakfast | -49.358 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.028 |
| 35 mg After Breakfast | 2.551 |
| 35 mg Before Breakfast | 2.496 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.177 |
| 35 mg After Breakfast | 2.821 |
| 35 mg Before Breakfast | 2.764 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.785 |
| 35 mg After Breakfast | 2.073 |
| 35 mg Before Breakfast | 2.075 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -46.261 |
| 35 mg After Breakfast | -51.079 |
| 35 mg Before Breakfast | -49.454 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -49.188 |
| 35 mg After Breakfast | -53.927 |
| 35 mg Before Breakfast | -53.186 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -43.075 |
| 35 mg After Breakfast | -45.705 |
| 35 mg Before Breakfast | -47.692 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -40.227 |
| 35 mg After Breakfast | -46.599 |
| 35 mg Before Breakfast | -44.630 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.223 |
| 35 mg After Breakfast | -47.263 |
| 35 mg Before Breakfast | -46.863 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.595 |
| 35 mg After Breakfast | -46.366 |
| 35 mg Before Breakfast | -45.420 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81.8 |
| 35 mg After Breakfast | 87.9 |
| 35 mg Before Breakfast | 90.1 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 82.6 |
| 35 mg After Breakfast | 89.2 |
| 35 mg Before Breakfast | 92.3 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81.5 |
| 35 mg After Breakfast | 87.4 |
| 35 mg Before Breakfast | 86.0 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81 |
| 35 mg After Breakfast | 87.5 |
| 35 mg Before Breakfast | 86.4 |
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 43 |
| Denosumab 60 mg Q6M | 26 |
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms [or both] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture). (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 264 |
| Denosumab 60 mg Q6M | 86 |
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 293 |
| Denosumab 60 mg Q6M | 238 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.35 |
| PTHrP 600 mcg/Day | -0.34 |
| PTH 20 mcg/Day | -0.82 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.91 |
| PTHrP 600 mcg/Day | 0.54 |
| PTH 20 mcg/Day | 0.61 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.48 |
| PTHrP 600 mcg/Day | -0.99 |
| PTH 20 mcg/Day | -0.97 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 1.89 |
| PTHrP 600 mcg/Day | 1.52 |
| PTH 20 mcg/Day | 2.17 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.68 |
| PTHrP 600 mcg/Day | 0.72 |
| PTH 20 mcg/Day | 0.54 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 42.51 | 65.25 | 67.29 | 58.15 | 53.73 |
| PTHrP 400 mcg/Day | 49.06 | 84.92 | 76.04 | 67.85 | 64.36 |
| PTHrP 600 mcg/Day | 42.49 | 63.07 | 65.15 | 57.02 | 55.08 |
(NCT00853723)
Timeframe: 90 days
| Intervention | mg/gm creatinine (Mean) | |
|---|---|---|
| Baseline | Day 90 | |
| PTH 20 mcg/Day | 209.99 | 232.48 |
| PTHrP 400 mcg/Day | 206.37 | 260.46 |
| PTHrP 600 mcg/Day | 213.07 | 235.25 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.87 | 13.89 | 52.98 | 92.46 |
| PTHrP 400 mcg/Day | -12.40 | 1.60 | 4.13 | 32.65 |
| PTHrP 600 mcg/Day | 10.25 | 9.59 | 14.38 | 25.65 |
(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | % excreted (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 2.30 | 2.55 | 2.92 | 2.95 | 3.37 |
| PTHrP 400 mcg/Day | 2.38 | 3.42 | 3.27 | 3.38 | 3.10 |
| PTHrP 600 mcg/Day | 2.71 | 4.18 | 3.74 | 2.89 | 2.89 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 60.67 | 97.27 | 125.46 | 171.49 |
| PTHrP 400 mcg/Day | 32.54 | 48.89 | 34.71 | 46.07 |
| PTHrP 600 mcg/Day | 23.51 | 83.14 | 87.39 | 84.09 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.09 | 4.13 | 4.19 | 4.28 | 4.10 |
| PTHrP 400 mcg/Day | 4.0 | 3.78 | 3.87 | 4.02 | 4.05 |
| PTHrP 600 mcg/Day | 3.93 | 3.68 | 3.71 | 3.97 | 3.98 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90, time 0 | Day 90, time 3 hours | day 90, time 6 hours | |
| PTH 20 mcg/Day | 9.49 | 9.57 | 9.55 | 9.58 | 9.44 | 9.75 | 9.78 |
| PTHrP 400 mcg/Day | 9.48 | 9.95 | 9.73 | 9.71 | 9.56 | 9.90 | 9.90 |
| PTHrP 600 mcg/Day | 9.51 | 9.87 | 9.67 | 9.61 | 9.45 | 9.76 | 9.81 |
"Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos~U= urine, P = plasma" (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 3.96 | 4.18 | 4.03 | 4.28 | 4.00 |
| PTHrP 400 mcg/Day | 3.80 | 3.78 | 3.88 | 4.02 | 4.11 |
| PTHrP 600 mcg/Day | 3.71 | 3.47 | 3.61 | 3.84 | 3.90 |
116 reviews available for etidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
History of risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2020 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Densit | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp | 2014 |
Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Topics: Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clini | 2015 |
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Drug Administration Sch | 2008 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Sp | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
[Etidronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Administration Schedule; Etidronic Aci | 2009 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects | 2009 |
Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cli | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; | 2011 |
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem | 2012 |
In brief: delayed-release risedronate (Atelvia).
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Delayed-Action Preparations; Etidronic A | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; | 2012 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation | 2013 |
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Topics: Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomized Controlled | 2002 |
Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, | 2002 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Estrogen Replacement Therapy; Etidronic A | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; F | 2003 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Es | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi | 2003 |
What predicts early fracture or bone loss on bisphosphonate therapy?
Topics: Alendronate; Etidronic Acid; Female; Forecasting; Fractures, Bone; Humans; Middle Aged; Osteoporosis | 2003 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle | 2003 |
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Ac | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; | 2004 |
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Topics: Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Mid | 2004 |
Risedronate for prevention and treatment of osteoporosis in postmenopausal women.
Topics: Animals; Bone Density; Bone Remodeling; Chemistry, Pharmaceutical; Clinical Trials as Topic; Etidron | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2005 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesi | 2005 |
Risedronate once a week.
Topics: Bone Density; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Humans | 2003 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; | 2005 |
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Etidronic | 2005 |
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Bo | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Est | 2006 |
[Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Congresses as Topic; | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
[Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature].
Topics: Administration, Oral; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Dr | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postme | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractu | 2007 |
WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures | 2007 |
WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
[HIP study--how to prevent hip fractures?].
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fr | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double- | 2007 |
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Osteo | 2008 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os | 2008 |
[Risedronate (Actonel)--from randomized clinical trials to real life].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Pos | 2007 |
Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today?
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Osteoporosi | 2007 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Treatment of osteoporosis.
Topics: Adult; Aged; Bone Resorption; Calcitonin; Calcium, Dietary; Combined Modality Therapy; Estrogen Repl | 1995 |
Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
Topics: Adult; Aged; Aging; Benzothiadiazines; Bone and Bones; Calcium; Diuretics; Estrogens; Etidronic Acid | 1995 |
Postmenopausal osteoporosis.
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1994 |
Treatment options for postmenopausal osteoporosis.
Topics: Calcitonin; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopaus | 1994 |
Treatment of postmenopausal osteoporosis with etidronate.
Topics: Administration, Oral; Adult; Bone Density; Calcium; Clinical Trials as Topic; Etidronic Acid; Female | 1993 |
Primary osteoporosis. Methods to combat bone loss that accompanies aging.
Topics: Adult; Age Factors; Aged; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Calcium; Causa | 1993 |
Office management of osteoporosis: a guide for the primary care provider.
Topics: Adolescent; Adult; Aged; Calcitonin; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic Acid; | 1995 |
Current and potential future drug treatments for osteoporosis.
Topics: Aged; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Male; Middl | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.
Topics: Bone Density; Calcitonin; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteo | 1997 |
Pathogenesis of the osteoporoses.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Female; Humans; Middle Aged; Osteocla | 1997 |
Osteoporosis: trials and tribulations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Estrogen Replaceme | 1997 |
The prevention and treatment of osteoporosis.
Topics: Adult; Aged; Calcitonin; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Middle Aged; | 1998 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 1998 |
Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aging; Alendronate; Bone Density; Clinical Trials as Topic; Data Collection; Etidronic Acid; Female; | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; | 1999 |
Etridronate therapy in the treatment and prevention of osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Osteop | 2000 |
Risedronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Adrenal Cortex Hormones; Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporos | 2000 |
[Osteoporosis in menopause: prevention and management].
Topics: Bone Density; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Menopause; Osteoporosis, | 1999 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Femal | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calci | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
Evidence-based medicine: putting theory into practice.
Topics: Alendronate; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based | 2001 |
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Post | 2001 |
Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Topics: Bone and Bones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Half-Life; Humans; I | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei | 2001 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; | 2001 |
Etidronate for treating and preventing postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Mi | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos | 2001 |
Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmeno | 2001 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Topics: Aged; Bone Density; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Huma | 2001 |
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Topics: Aged; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Bone; Humans; MEDLINE; Osteoporos | 2002 |
Calcitriol and postmenopausal osteoporosis.
Topics: Anabolic Agents; Bone Density; Calcitriol; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic | 1992 |
Etidronate for vertebral osteoporosis after the menopause.
Topics: Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spine | 1992 |
Menopause: advanced management strategies.
Topics: Calcium; Estrogen Replacement Therapy; Etidronic Acid; Female; Fluorides; Humans; Menopause; Middle | 1991 |
Bisphosphonate therapy for osteoporosis.
Topics: Bone Density; Bone Regeneration; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; H | 1991 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1991 |
[Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
Topics: Aged; Bone Density; Calcitonin; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combinat | 1991 |
Treatment of osteoporosis: current and future.
Topics: Aged; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postm | 1991 |
New treatments for osteoporosis.
Topics: Bone Density; Bone Development; Bone Resorption; Drug Administration Schedule; Etidronic Acid; Femal | 1990 |
170 trials available for etidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2022 |
Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Ch | 2013 |
Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Incidence; Ost | 2014 |
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents | 2014 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractu | 2014 |
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; | 2015 |
Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Cross-Over Stud | 2015 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo | 2008 |
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Anabolic Agents; Bone Density Conservation Agents; | 2008 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents | 2009 |
Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial.
Topics: Anti-Asthmatic Agents; Asthma; Bone Density Conservation Agents; Cohort Studies; Estrogen Replacemen | 2009 |
Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; | 2009 |
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I | 2009 |
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response R | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2009 |
Risedronate reduces intracortical porosity in women with osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Demography; Etidronic Acid; Fe | 2010 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone | 2010 |
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosp | 2009 |
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Double-Blind | 2010 |
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Hu | 2009 |
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Topics: Adult; Age Factors; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Dose-Resp | 2009 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Effects of risedronate on bone marrow adipocytes in postmenopausal women.
Topics: Adipocytes; Adipogenesis; Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Et | 2011 |
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Drug Admini | 2010 |
Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Topics: Bone Density Conservation Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.
Topics: Aged; Ankle Brachial Index; Bone Density; Bone Density Conservation Agents; Carotid Arteries; Etidro | 2010 |
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etid | 2012 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci | 2011 |
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Et | 2011 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Ag | 2011 |
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparati | 2012 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density | 2012 |
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid | 2012 |
Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2012 |
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind | 2013 |
Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Analgesics; Back Pain; Bone Density; Bone Density Conservation Agents; Calc | 2012 |
Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone | 2012 |
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparati | 2013 |
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Admi | 2013 |
Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Creatinine; | 2013 |
[Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis].
Topics: Aged; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Female; Humans; Middle Aged; Ost | 2011 |
Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Screws; Etidronic Acid | 2013 |
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Dru | 2002 |
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Incidence; Osteoporosis, Postmenopau | 2003 |
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
Topics: Aged; Aged, 80 and over; Bone Density; Confidence Intervals; Etidronic Acid; Female; Humans; Osteopo | 2003 |
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2003 |
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Topics: Aged; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Humans; Middl | 2003 |
Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Chromatography, High Pressure Liq | 2003 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Ac | 2003 |
Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density; Calcium; Collagen; Collagen Type I; E | 2003 |
Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Resorption; Drug Therapy, Combination; Etidronic Acid; F | 2003 |
Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Topics: Absorptiometry, Photon; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C | 2003 |
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Remodeling; Densitometry; Dose-Response Relationship, D | 2003 |
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Fractures | 2004 |
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Topics: Aged; Biopsy; Bone and Bones; Etidronic Acid; Female; Humans; Imaging, Three-Dimensional; Osteoporos | 2004 |
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Humans; Lumbar Verteb | 2004 |
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Height; Bone and Bones; Collagen; Collagen | 2004 |
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic | 2004 |
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; | 2004 |
RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.
Topics: Adjuvants, Immunologic; Aged; Bone Density; Calcitonin; Estrogen Replacement Therapy; Etidronic Acid | 2004 |
Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Canada; Cohort Studies; Collagen; Collagen Type I; Etidron | 2004 |
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Calcium Channel Blockers; Double-Blind Method; Etidronic A | 2004 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conserv | 2006 |
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Topics: Aged; Alendronate; Biomarkers; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Double-Bli | 2005 |
Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcaneus; Calcium; Dietary Supplements; | 2005 |
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Topics: Asian People; Biomarkers; Bone Density; Bone Remodeling; Etidronic Acid; Female; Humans; Middle Aged | 2005 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, C | 2005 |
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Topics: Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Etidronic Acid; Fema | 2005 |
The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Topics: Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Data Inter | 2005 |
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; I | 2005 |
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
Topics: Bone Density; Double-Blind Method; Etidronic Acid; Humans; Meta-Analysis as Topic; Osteoporosis, Pos | 2005 |
Cyclical alendronate treatment in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Density Conservation Agents; Calc | 2005 |
Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation | 2005 |
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Topics: Absorptiometry, Photon; Adult; Amino Acids; Biomarkers; Bone Density Conservation Agents; Creatinine | 2005 |
Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Eti | 2005 |
Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur | 2006 |
Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Metho | 2006 |
Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Etidronic Acid; | 2006 |
Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Calcium; Collage | 2006 |
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Etidron | 2007 |
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Human | 2006 |
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; E | 2007 |
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Etidronic Aci | 2007 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fem | 2007 |
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans | 2007 |
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collage | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Fe | 2007 |
Monitoring of Risedronate by biochemical bone markers in clinical practice.
Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo | 2005 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Middl | 2008 |
Fracture risk remains reduced one year after discontinuation of risedronate.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Collag | 2008 |
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
Topics: Aged; Bone Density Conservation Agents; Calcium; Cell Survival; Cells, Cultured; Colony-Forming Unit | 2008 |
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Collagen Type I; Drug Administration Sche | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; | 2008 |
Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Meth | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Collagen Type I; Etidronic Acid; Female | 2008 |
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bo | 2008 |
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resor | 2008 |
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Topics: Absorptiometry, Photon; Aged; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Fem | 2008 |
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Die | 2008 |
Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Topics: Absorptiometry, Photon; Bone Density; Drug Therapy, Combination; Ergocalciferols; Etidronic Acid; Fe | 1995 |
A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Topics: Administration, Oral; Aged; Bone Density; Calcium; Drug Administration Schedule; Drug Therapy, Combi | 1994 |
Antiresorptive drugs and trabecular bone turnover: validation and testing of a computer model.
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Bone Resorp | 1994 |
Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Bone Density; Drug Administration Schedule; Etidro | 1994 |
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.
Topics: Bone and Bones; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Human | 1994 |
[A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].
Topics: Alkaline Phosphatase; Bone Density; Calcium; Drug Evaluation; Estradiol; Etidronic Acid; Female; Hum | 1993 |
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Topics: Analysis of Variance; Bone Density; Double-Blind Method; Drug Administration Schedule; Etidronic Aci | 1993 |
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Double-Blind Method; Etidronic Acid; Female; H | 1993 |
The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women.
Topics: Bone Density; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Fema | 1993 |
Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Topics: Aged; Bone Density; Disease Progression; Double-Blind Method; Drug Administration Schedule; Etidroni | 1996 |
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Topics: Adult; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Do | 1997 |
The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium; Calcium, Dietary; Drug Therapy, Combination; Et | 1997 |
A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total-body DXA.
Topics: Absorptiometry, Photon; Bone Density; Double-Blind Method; Etidronic Acid; Female; Hip; Humans; Long | 1996 |
Cyclical etidronate prevents spinal bone loss in early post-menopausal women.
Topics: Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Etidronic Acid; Female; Humans; Lumbar | 1997 |
Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
Topics: Absorptiometry, Photon; Administration, Intranasal; Aged; Analysis of Variance; Biomarkers; Bone Den | 1997 |
Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.
Topics: Alkaline Phosphatase; Biomarkers; Collagen; Collagen Type I; Creatinine; Etidronic Acid; Female; Fra | 1997 |
Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Clodronic Acid; Collagen; Collagen Type I | 1997 |
The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study.
Topics: Aged; Bone Density; Calcitriol; Cohort Studies; Etidronic Acid; Female; Femoral Neck Fractures; Huma | 1997 |
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)
Topics: Biomarkers; Bone and Bones; Bone Density; Double-Blind Method; Drug Administration Schedule; Etidron | 1997 |
The effect of weight change on DXA scans in a 2-year trial of etidronate therapy.
Topics: Absorptiometry, Photon; Aged; Algorithms; Body Weight; Bone Density; Double-Blind Method; Etidronic | 1997 |
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Double-Blind Method | 1997 |
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Topics: Aged; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; | 1997 |
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Bone Density; Calcium Channel Blockers; Creatinine; Double | 1998 |
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Drug Administration Schedule; Drug Therapy, Combination; Estrogen Replacement Th | 1998 |
Highly precise peripheral quantitative computed tomography for the evaluation of bone density, loss of bone density and structures. Consequences for prophylaxis and treatment.
Topics: Adult; Aged; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy; Etidr | 1998 |
Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Calcitriol; Drug Therapy, Comb | 1998 |
Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Bon | 1999 |
An unexpected change in DXA calibration not detected by routine quality control checks.
Topics: Absorptiometry, Photon; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Fem | 1999 |
[Treatment of postmenopausal osteoporosis with etidronate].
Topics: Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1999 |
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Fema | 1999 |
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Australia; Bone Density; Calcium Channe | 2000 |
VDR genotype and response to etidronate therapy in late postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Calcium; Etidronic Acid; Female; Genotype; Humans; Hydroxyproline; L | 1999 |
The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study.
Topics: Absorptiometry, Photon; Adult; Analysis of Variance; Bone Density; Etidronic Acid; Female; Femur; Hu | 2000 |
Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Topics: Amino Acids; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Drug Administration Sch | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Acute effects of etidronate on glucocorticoid-induced bone degradation.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcium; Drug Therapy, Combination; Etidronic Acid; Female; Hom | 2000 |
Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.
Topics: Administration, Oral; Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, | 2000 |
Monitoring skeletal response to treatment which site to measure in the femur?
Topics: Absorptiometry, Photon; Administration, Oral; Bone Density; Double-Blind Method; Etidronic Acid; Fem | 2000 |
Prevention of early postmenopausal bone loss with cyclical etidronate.
Topics: Absorptiometry, Photon; Amino Acids; Bone Density; Double-Blind Method; Etidronic Acid; Female; Femu | 2000 |
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Fem | 2000 |
Response to alendronate in osteoporosis after previous treatment with etidronate.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Cohort Studies; Etidronic Acid; Female; Hum | 2000 |
Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women.
Topics: Adult; Aged; Aspirin; Duodenal Ulcer; Endoscopy, Gastrointestinal; Esophagus; Etidronic Acid; Female | 2000 |
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
Topics: Aged; Calcium Channel Blockers; Collagen; Cross-Linking Reagents; Double-Blind Method; Etidronic Aci | 2001 |
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, | 2001 |
A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodelin | 2000 |
The effect of weight change on total body dual-energy X-ray absorptiometry: results from a clinical trial.
Topics: Absorptiometry, Photon; Aged; Body Weight; Bone Density; Double-Blind Method; Etidronic Acid; Female | 2000 |
Prevention of secondary osteoporosis postmenopause in hemiplegia.
Topics: Absorptiometry, Photon; Activities of Daily Living; Aged; Alkaline Phosphatase; Amino Acids; Bone De | 2001 |
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replace | 2001 |
Response of cortical bone to antiresorptive treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone and Bones; Bone Density; Etidronic Acid; Female; Hor | 2001 |
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis.
Topics: Aged; Calcium Compounds; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Hydroxycholecalc | 2001 |
Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Densitometry; Drug Therapy, Combination; Etid | 2001 |
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
Topics: Absorptiometry, Photon; Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosi | 2001 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal | 2001 |
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos | 2002 |
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Huma | 2002 |
Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years.
Topics: Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Middle | 1992 |
The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.
Topics: Aged; Bone Density; Bone Remodeling; Drug Administration Schedule; Drug Therapy, Combination; Etidro | 1991 |
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Bone and Bones; Bone Resorption; Double-Blind Method; Drug Administratio | 1990 |
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Fema | 1990 |
193 other studies available for etidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid | 2023 |
History of etidronate.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; History, 20t | 2020 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Teriparatide vs risedronate for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Teriparatide vs risedronate for osteoporosis - Authors' reply.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Finite Ele | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2013 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Coh | 2014 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
Topics: Aged; Biomarkers; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporos | 2008 |
Risedronic acid and calcium + colecalciferol: new combination. A simple combination of two other products. A simple commercial ploy with no benefit for patients.
Topics: Calcium; Drug Approval; Drug Therapy, Combination; Ergocalciferols; Etidronic Acid; Female; France; | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analys | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fr | 2009 |
Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Collagen Type I; Diph | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
Topics: Aged; Bone Density Conservation Agents; Canada; Decision Making; Epidemiologic Methods; Etidronic Ac | 2009 |
Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.
Topics: Bone Density Conservation Agents; Calcium Compounds; Data Collection; Diphosphonates; Drug Combinati | 2009 |
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates | 2009 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr | 2008 |
[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drugs, Gene | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; D | 2009 |
Risedronate on two consecutive days per month.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Medi | 2009 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Diseas | 2009 |
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Ana | 2010 |
[Acute exacerbation of a chronic esophagitis].
Topics: Acute Disease; Anti-Bacterial Agents; Bone Density Conservation Agents; Clindamycin; Diagnosis, Diff | 2009 |
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Topics: Aged; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Female; Humans; Model | 2010 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg | 2010 |
Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Bone Density Conservation Agents; Diphosphonates; Eti | 2010 |
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Stu | 2010 |
Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.
Topics: Aged; Aorta, Abdominal; Atherosclerosis; Body Mass Index; Bone Density Conservation Agents; Calcinos | 2010 |
Risedronate-induced arthritis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoarthritis; Osteo | 2010 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2011 |
Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Asian People; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Japan; Osteopo | 2011 |
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Frac | 2011 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Re | 2011 |
Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
Topics: Aged; Antioxidants; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Free Rad | 2012 |
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Densit | 2012 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Density; Bone Density Conservation Age | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian Peopl | 2012 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2013 |
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2012 |
Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal.
Topics: Adipocytes; Alkaline Phosphatase; Animals; Apoptosis; Bone Density Conservation Agents; Cell Differe | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Co | 2013 |
Non-invasive assessment of bone quality.
Topics: Aged; Aged, 80 and over; Animals; Bone and Bones; Bone Density; Cadaver; Disease Models, Animal; Ela | 1999 |
Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effects of etidronate treatment.
Topics: Aged; Biopsy; Etidronic Acid; Female; Humans; Ilium; Middle Aged; Osteoporosis, Postmenopausal; Tomo | 2002 |
[Treatment of a solitary adenoma of the parathyroid gland with ultrasound-guided percutaneous Radio-Frequency-Tissue-Ablation (RFTA)].
Topics: Adenoma; Aged; Bone Density; Calcium; Catheter Ablation; Cholecalciferol; Etidronic Acid; Female; Fo | 2002 |
[Osteoporosis therapy. A comparison of bisphosphonates].
Topics: Aged; Alendronate; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Random | 2002 |
Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cause of Death; Clinical Trials, Phase III | 2002 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal | 2002 |
[Treatment of osteoporosis. Not only measurements count].
Topics: Biopsy; Bone and Bones; Bone Density; Clinical Trials as Topic; Etidronic Acid; Humans; Middle Aged; | 2002 |
Once-a-week risedronate (actonel).
Topics: Administration, Oral; Digestive System; Diphosphonates; Dose-Response Relationship, Drug; Drug Admin | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures | 2002 |
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Dose-Response Relationship, | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated | 2002 |
[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
Topics: Aged; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Spo | 2003 |
[Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it].
Topics: Bone Density; Diphosphonates; Double-Blind Method; Etidronic Acid; Family Practice; Female; Follow-U | 2003 |
Bone density changes with once weekly risedronate in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Digestive System; Diphosphonates; Drug Tolerance; Et | 2003 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe | 2003 |
Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrog | 2003 |
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].
Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteop | 2003 |
[To treat effectively without delay. The data on fractures decisive].
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dipho | 2003 |
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].
Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans | 2003 |
Compliance with pharmacologic therapy for osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Estrogens; Etidronic | 2003 |
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.
Topics: Aged; Alendronate; Analysis of Variance; Canada; Diphosphonates; Drug Therapy, Combination; Etidroni | 2003 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Os | 2003 |
[Osteoporosis therapy. Bisphosphonates compared].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Etidronic | 2003 |
Efficacy of risedronate on clinical vertebral fractures within six months.
Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; R | 2004 |
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Fema | 2003 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Risedronate affects bone strength, too. Faster protective effect on microarchitecture].
Topics: Bone and Bones; Calcium Channel Blockers; Collagen; Etidronic Acid; Female; Humans; Middle Aged; Ost | 2004 |
[Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
Topics: Alendronate; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter | 2004 |
[Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractu | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic | 2004 |
[FACT study: benefits of alendronate].
Topics: Aged; Alendronate; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Fema | 2005 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporos | 2005 |
[Evaluation of the effects of treatment of osteoporosis].
Topics: Aged; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female | 2005 |
Potential impact of osteoporosis treatment on hip fracture trends.
Topics: Aged; Bone and Bones; Bone Density; Canada; Clinical Trials as Topic; Etidronic Acid; Female; Hip Fr | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidroni | 2005 |
[Excellent adjustment with greater action. To pay attention to improving compliance].
Topics: Aged; Calcium; Clinical Trials as Topic; Cross-Over Studies; Diphosphonates; Drug Packaging; Drug Th | 2005 |
[Marketing--alendronate versus risedronate].
Topics: Alendronate; Bone Density; Drug Information Services; Etidronic Acid; Humans; Marketing; Osteoporosi | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Hospitalization-related bone loss and the protective effect of risedronate.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur | 2006 |
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female | 2005 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidr | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
One drug tackles two diseases.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; | 2005 |
[What do we need to know--what can we do?].
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium Channel Blockers; C | 2005 |
Osteoporosis management in a Medicaid population after the Women's Health Initiative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2006 |
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Health Care Costs; Huma | 2006 |
Pseudogout attack induced during etidronate disodium therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Chondrocalcinosis; Etidro | 2006 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Dip | 2006 |
[Management of corticosteroid-induced osteoporosis].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Calcium; Cortisone; Dip | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; E | 2006 |
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid | 2006 |
Risedronate-induced Hepatitis.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Dose-Re | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Topics: Absorptiometry, Photon; Aged; Biopsy; Bone and Bones; Bone Density Conservation Agents; Bone Remodel | 2007 |
[Men also need bone protection].
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2006 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonat | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-B | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic | 2008 |
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Cohort Studies; Databases, Factual; Diphospho | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease.
Topics: Aged; Bone Density Conservation Agents; Chronic Disease; Etidronic Acid; Female; Fractures, Bone; He | 2008 |
Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Biomechanical Phenomena; Blood Chemical Analy | 1995 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe | 1995 |
Intermittent cyclic etidronate treatment of postmenopausal osteoporosis.
Topics: Aged; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postm | 1995 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni | 1995 |
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis.
Topics: Aged; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postm | 1995 |
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remode | 1995 |
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci | 1995 |
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An | 1995 |
Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis.
Topics: Aged; Biomarkers; Etidronic Acid; Female; Femoral Neck Fractures; Foot Injuries; Fractures, Stress; | 1994 |
Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
Topics: Bone Density; Calcium; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis | 1994 |
[Didrokit (etidronic acid-calcium carbonate) in the treatment of postmenopausal osteoporosis improperly recorded?].
Topics: Calcium Carbonate; Drug Combinations; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1994 |
[Didrokit (etidronic acid-calcium carbonate) for the treatment of postmenopausal osteoporosis improperly recorded?].
Topics: Calcium Carbonate; Drug Combinations; Etidronic Acid; Female; Humans; Netherlands; Osteoporosis, Pos | 1994 |
Etidronate [correction of etridronate] therapy for Kaposi's sarcoma? letter.
Topics: Aged; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Sarcoma, Kaposi | 1994 |
[Didrokit (etidronic acid-calcium carbonate) for the treatment of postmenopausal osteoporosis recorded improperly?].
Topics: Aged; Calcium Carbonate; Drug Combinations; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosi | 1994 |
Osteoporosis. ACOG technical bulletin number 167--May 1992.
Topics: Absorptiometry, Photon; Calcitonin; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; In | 1993 |
Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study.
Topics: Aged; Bone Density; Etidronic Acid; Female; Fluorides; Humans; Magnesium; Middle Aged; Osteoporosis, | 1993 |
Postmenopausal osteoporosis: patient choices and outcomes.
Topics: Aged; Aged, 80 and over; Bone Density; Calcitonin; Choice Behavior; Estrogen Replacement Therapy; Et | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal | 1995 |
Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis.
Topics: Aged; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteomalacia; Oste | 1995 |
A comparison of the effectiveness and cost of treatment for vertebral fractures in women.
Topics: Aged; Calcitonin; Cost-Benefit Analysis; Estrogen Replacement Therapy; Etidronic Acid; Female; Human | 1995 |
Cyclical etidronate and calcium carbonate (with citrate) supplementation for osteoporosis unmasking primary hyperparathyroidism.
Topics: Aged; Aged, 80 and over; Antacids; Calcium; Calcium Carbonate; Citrates; Citric Acid; Diagnosis, Dif | 1995 |
New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis.
Topics: Adult; Aged; Amino Acids; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Collagen; | 1996 |
Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Calcium; Creati | 1996 |
A tale of two worlds in prescribing etidronate for osteoporosis.
Topics: Alendronate; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1997 |
[Etidronate versus alendronate].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
[Osteoporosis treatment: the point of view of the gynecologist].
Topics: Age Factors; Bone Density; Calcitonin; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Fema | 1998 |
Effects of exercise training and etidronate treatment on bone mineral density and trabecular bone in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Models, Animal; Etidronic Acid; Female; Femur | 1998 |
Further hearing loss during osteoporosis treatment with etidronate.
Topics: Aged; Etidronic Acid; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Osteoporosis, | 1998 |
Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Topics: Anabolic Agents; Bone Density; Calcium; Drug Therapy, Combination; Etidronic Acid; Female; Humans; M | 1998 |
Re: Use of cyclic etidronate and the prevention of non-vertebral fractures.
Topics: Aged; Clinical Trials as Topic; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bon | 1998 |
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Calcium; Cost-Benefit Analysis; Drug Therapy, Combination; Estradiol; Estrogen Re | 1998 |
Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Osteoporosis, Po | 1998 |
Risedronic acid. NE 58095, risedronate sodium, Actonel.
Topics: Aged; Animals; Drugs, Investigational; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Os | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
Conference report--scientific and clinical developments in osteoporosis.
Topics: Bone Density; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Estrogen Receptor beta; Est | 1999 |
Cyclical etidronate use is not associated with symptoms of peptic ulcer disease.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Cohort Studies; Estrogens; Etidronic Acid; Female; Follo | 2000 |
Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis.
Topics: Arthritis, Rheumatoid; Cost-Benefit Analysis; Estrogen Replacement Therapy; Etidronic Acid; Female; | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a | 2001 |
The role of combination treatment for osteoporosis.
Topics: Aged; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bo | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Info | 2001 |
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2001 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru | 2001 |
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
Topics: Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Follow-Up Stud | 2001 |
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
Topics: Aged; Clinical Trials as Topic; Drug Approval; Etidronic Acid; Female; Femoral Neck Fractures; Fract | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop | 2001 |
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
Topics: Biometry; Endpoint Determination; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Rand | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
[Therapy of osteoporosis. Risk factors alone are not an indication].
Topics: Aged; Aged, 80 and over; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Oste | 2001 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic A | 2002 |
The cost utility of bisphosphonate treatment in established osteoporosis.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans | 2002 |
Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women.
Topics: Absorptiometry, Photon; Aged; Bone Density; Case-Control Studies; Etidronic Acid; Exercise; Female; | 2002 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |
[Treatment of common osteoporosis].
Topics: Aged; Estrogens; Etidronic Acid; Female; Femoral Fractures; Humans; Middle Aged; Osteoporosis, Postm | 1991 |
Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women.
Topics: Aged; Bone Density; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; | 1991 |
Etidronate and osteoarthritis.
Topics: Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoarthritis; Osteoporosis, Postmeno | 1991 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Bone Density; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopa | 1991 |
Pseudogout associated with the use of cyclical etidronate therapy.
Topics: Aged; Chondrocalcinosis; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, | 1991 |
Selections from current literature: hormone therapy in postmenopausal women.
Topics: Calcium, Dietary; Cardiovascular Diseases; Estrogen Replacement Therapy; Etidronic Acid; Female; Hum | 1991 |
A new option for treating osteoporosis.
Topics: Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1990 |
Osteoporosis after 60.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Po | 1990 |
Etidronate for postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures | 1990 |
Cyclical etidronate treatment of osteoporosis.
Topics: Binding, Competitive; Bone and Bones; Diphosphonates; Etidronic Acid; Female; Humans; Hypercalcemia; | 1990 |
Etidronate for postmenopausal osteoporosis.
Topics: Clinical Trials as Topic; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal | 1990 |